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 SUMMARY 
The structural and functional complicity of the central nervous system (CNS) 
and the unavailability of effective conventional therapies pose great challenges 
to effective treatment of CNS diseases, which include neurodegenerative 
diseases and brain tumors. Gene therapy has been viewed as one of the most 
promising approaches to address these problems and gene delivery vectors 
with high transfer efficiency are in great demand. The purpose of this study 
was to explore the possibility of using currently available chemical drugs or 
molecules to improve the gene transfer efficiency of non-viral and viral vectors.  
 
We first tested a new non-viral vector of polyethylenimine(PEI)-based 
copolymer synthesized by linking less toxic, low molecular weight PEIs with a 
commonly used, biocompatible drug carrier, cyclodextrin (CyD). In cell viability 
assays with neural cells, the copolymer performed similarly as low molecular 
weight PEIs and displayed much lower cellular cytotoxicity when compared to 
PEI 25kDa. Gene delivery efficiency of the copolymer was comparable to and, 
at higher polymer/DNA (N/P) ratios, even higher than that offered by 25 kDa 
PEI. Attractively, injection of plasmid DNA complexed with the copolymer into 
CNS resulted in detectable gene expression that is much higher than that of 
low MW PEI, although still slightly lower than that offered by PEI 25kDa.  
 
The second part of this work was to investigate the possibility of enhancing 
PEI-mediated gene expression in multidrug resistant tumor cells by inhibiting 
the drug efflux pump P-Glycoprotein (PGP) with pharmaceutical or biological 
 IX
molecules. By analyzing PEI/DNA complex-mediated transgene expression in 
tumor cells with different expression levels of PGP, lower level of transgene 
expression in PGP-positive cells was observed compared to that in 
PGP-negative cells, and the low level of PEI-mediated transgene expression in 
PGP-positive cells were enhanced dramatically by pre-treating the cells with 
PGP inhibitor verapamil. Furthermore, down-regulation of PGP expression by 
siRNAs specifically targeting MDR1 gene that encodes PGP protein 
remarkably enhanced PEI-mediated transgene expression in these 
PGP-positive cells.  
 
In the third part of this work, the transgene delivery efficiency of a newly 
emerged viral vector, baculovirus vector, was investigated after combining it 
with sodium butyrate, a histone deacetylase (HDAC) inhibitor. The 
co-treatment was tested in cell lines of glioblastoma multiforme (GBM), one of 
the lethal diseases in humans. The addition of sodium buryrate in baculovirus 
mediated gene delivery greatly enhanced baculovirus-mediated gene transfer 
efficiency. Especially, co-treatment of GBM cells which contain a mutant type 
p53 gene by baculovirual vectors with wild type p53 (wtp53) gene and sodium 
butyrate exhibited synergistic anti-tumor effects both in vitro and in vivo.  
 
In conclusion, this study presented novel approaches to improve gene delivery 
efficiency of non-viral and viral vectors by using chemical or biological 
molecules, which would be worth exploring further as practical strategies for 
future gene therapy for CNS diseases.  
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Chapter 1 Introduction 
1.1 Current progress in gene therapy 
Gene therapy can be broadly defined as the treatment of a disease through the 
addition of genetic materials that reconstitute or correct missing or aberrant 
genetic functions, or interfere with disease-causing processes(Factor, 2001). 
The original goal of gene therapy was to correct a genetic disorder by inserting 
a functional gene into an organism to replace an inherited defective one. 
However, recently gene therapy has also been used in the treatment of 
diseases other than inherited single gene disorders (Dachs et al., 1997). 
 
There are three very important components that need to be considered for an 
effective gene therapy: gene delivery systems (vectors), regulatory elements 
and therapeutic genes. The vectors refer to the carriers of transgene into 
target cells, and they have been commonly divided into viral and non-viral 
vectors. Regulatory elements are DNA sequences used for the control of the 
transgene expression and generally determine the specificity and expression 
level of the transgene(s). Therapeutic genes are the transgenes delivered into 
target cells, which have functional therapeutic effects to ameliorate the 
diseases. The most ideal human gene therapy is the perfect combination of 
these three components to generate a safe and effective way for the delivery 
of genes into the patient and subsequent treatment of the disease by the 
transgene. In the current stage of gene therapy, most efforts are still being 
made to develop safer and more efficient gene delivery vectors. 
 
1.2 Gene delivery vectors in central nervous system (CNS)  
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In the past decades, more than 400 clinical gene therapy studies have been 
evaluated, yet only a few have been directed to diseases of the nervous 
system, including the treatment of neurodegenerative disorders such as 
amyotrophic lateral sclerosis, as well as brain tumors such as neuroblastoma 
and Glioblastoma multiforme (GBM) (Hsich et al., 2002). This is largely 
undesirable because these diseases are potentially amenable to gene therapy 
given the ineffectiveness of conventional treatments such as drug treatment or 
chemotherapy. However, this also reflects the unique difficulties in designing 
appropriate gene therapy strategies for the complicated CNS.  
 
Gene delivery to CNS is complicated by the high risk and limited access to the 
brain, as well as the high compartmentalization, huge diversity of cell types 
and complex circuitry within the brain (Hsich et al., 2002). Despite these 
difficulties, with the enormous increase of knowledge concerning the molecular 
biology of CNS and extensive application of animal models for CNS diseases, 
gene therapy for CNS diseases has drawn tremendous attention in recent 
years, especially in developing novel gene delivery vectors for CNS. Gene 
therapy for different diseases may require gene delivery vectors with various 
characteristics, therefore choosing the right vector for particular diseases 
should always be taken into the first consideration. In this thesis, i would like to 
focus on the gene delivery vectors for gene therapy in CNS. Although an ideal 
gene delivery vector requires high efficiency with no side effects such as 
cytotoxicity and immunogenecity, the current non-viral and viral vectors have 
their own respective advantages for gene therapy. In the following sections, 
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several commonly used non-viral and viral gene delivery vectors will be 
reviewed for their characteristics. 
 
1.2.1 Non-viral vectors  
Non-viral vectors include naked DNA, cationic lipids and cationic polymers. 
According to their delivery methods, non-viral vectors can be divided into two 
broad categories, physical methods and chemical methods. Physical methods 
involve taking plasmids and forcing them into cells through such means as 
electroporation, and particle bombardment, which are generally used for naked 
DNA delivery. Chemical methods use a large range of chemical agents such 
as lipids and polymers as carrier molecules that will complex with DNA, 
condensing it into particles and directing it to the cells. 
 
1.2.1.1 Naked DNA 
The simplest way for administration of DNA is direct injection of naked plasmid 
DNA into the tissue or vessel without any chemical carriers. Naked DNA can 
give efficient gene transfer in muscle in vivo with expression of transgene 
persisting for longer than 2 months (Wolff et al., 1990). Numerous other 
tissues have also been shown to be susceptible to naked DNA mediated 
transfection in vivo including the brain but with very low efficiency (Schwartz et 
al., 1996). Thus naked DNA has been restricted in their use for gene therapy 
because of their poor transduction efficiency. Various physical manipulations 
have been used to improve the efficiency, including electroporation, particle 
bombardment, hydrodynamic pressure, and microinjection of DNA. However, 
these methods have been limited by tedious technologies for in vivo 
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application. Even like hydrodynamic pressure techniques which is easy to be 
carried out by tail injection, it might be amenable to use in humans due to the 
increase of blood pressure. 
 
1.2.1.2 Cationic lipids 
Cationic lipids are known to be chemical carriers for gene delivery, capable of 
interacting with and condensing negatively charged DNA through electrostatic 
interactions, which is necessary for transfecting most of the cell types. The 
cationic lipids, when complexed with plasmid DNA to form liposomes, have 
been shown to be highly successful in transfecting cell lines (Mahato et al., 
1997; Pedroso de Lima et al., 2001; Yoshida et al., 2001), which could be used 
for ex vivo gene therapy approaches. Many cationic lipid compounds have 
been developed. Therapeutic genes such as Herpes simplex virus 1 thymidine 
kinase (HSV-1 TK) have been successfully delivered into glioma cells 
(Yoshida et al., 2001; Zerrouqi et al., 1996). These developments have led to 
clinical trials using cationic liposomes mediated gene therapy for the treatment 
of cancer. However, using cationic lipid for gene delivery has been limited due 
to its instability and poor targeting to specific tissues.  
 
1.2.1.3 Cationic polymers 
Like cationic lipids, highly cationic charged polymers also act as chemical 
carriers to condense DNA via non-specific electrostatic interactions. The use 
of cationic polymer such as polyethylenimine (PEI) displays striking 
advantages in gene delivery as compared to naked DNA and cationic lipids. 
Polymers can be specifically tailored for particular applications by choosing 
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appropriate molecular weights, designing cell or tissue specific targeting 
moieties and so on.    
 
Poly(L-lysine) is one of the first polymers used as a non-viral vector. 
Poly(L-lysine) is biodegradable due to its peptide structure. However the 
transfection efficiency mediated by poly(L-lysine) is very low, which may be 
due to the lack of amino groups and subsequent lack of endosomolysis 
(Merdan et al., 2002). Some other polymers such as chitosans are also limited 
in gene delivery applications with their poor endosomolysis ability (Merdan et 
al., 2002). There are only a few polymers that have intrinsic endosomolytic 
property, among which PEI is the one with the highest charge density and a 
high intrinsic endosomolytic activity (Kircheis et al., 2001b). 
 
PEI has in fact become the standard for non-viral gene vectors. PEI is 
available in two forms: linear and branched. The branched form is synthesized 
by acid-catalyzed polymerization of azridine monomers, which result in the 
formation of random branched polymers. The linear form is produced by a 
similar process but at lower temperature (Godbey et al., 1999). The particular 
characteristic of PEI polymer is the high intrinsic endosomolytic activity 
conferred by the strong buffer capacity over a wide pH range (Boussif et al., 
1995; Kircheis et al., 2001b). PEI is thought to function as a proton sponge, 
with the protonation triggering passive chloride ion movement. The 
accumulation of proton and chloride ion results in osmotic swelling and 
endosome rupture, thus releasing the PEI/DNA complexes into the cytosol 
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(Boussif et al., 1995). This property is likely to be one of the important factors 
for the high transfection efficiency offered by PEI polymers. 
 
Different molecular weights and /or branching degrees of PEI have been 
synthesized and evaluated in vitro as well as in vivo (Fischer et al., 1999). The 
PEI polymers with high molecular weight generally have higher transfection 
efficiencies compared to other non-viral vectors. Gene delivery using PEI 
involves condensation of DNA into compact particles, uptake into the cells, 
release from the endosomal compartment into the cytoplasm, and uptake of 
the DNA into the nucleus. This multi-step process indicates that there are 
many factors affecting the transfection efficiency of PEI, including particle size, 
molecular weight (MW), structure (branch or linear), and surface charge. For 
branched PEI 25kDa/DNA and branched PEI 800kDa/DNA complexes, 
transfection efficiency was found to correlate with the particle size, with small 
particles having significantly lower transfection efficiency than larger particles 
(Ogris et al., 1999; Ogris et al., 1998). It was also reported that high MW PEI 
often had relatively higher transfection efficiency and toxicity compared to low 
MW PEI (Baker and Cotten, 1997; Boussif et al., 1996; Kichler et al., 2002). 
The toxicity of high molecular weight PEI has been proposed to be due to 
positively charged PEI/DNA particles interacting with blood components such 
as erythrocytes and causing embolism by aggregation in the lung capillaries 
(Kircheis et al., 1999; Kircheis et al., 2001a; Ogris et al., 1998). High MW PEI 
polymers were also reported to induce rapid necrotic-like changes resulting 
from perturbation of the plasma membrane, followed by activation of the 
mitochondria-mediated apoptosis (Moghimi et al., 2005). The inverse 
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relationship between transfection efficiency and cytotoxicity of PEI has limited 
the use of PEI-mediated gene delivery system in vivo and thus it is necessary 
to find ways to solve the problem before any bench-to-clinic translational 
application can be carried out. Moreover, as the positively charged PEI/DNA 
complexes interact with the negatively charged cell membrane via non-specific 
electrostatic interaction, further modifications are also needed for PEI in order 
to mediate specific cell targeting gene delivery. 
 
1.2.1.4 Chemical modifications of PEI to facilitate gene delivery 
Various modifications of PEI have been explored in recent years in an effort to 
enhance its transfection efficiency, improve targeting specificity as well as 
reduce the toxicity. Most of the modifications involve chemical conjugation to 
achieve specific purpose, which indicate a practical way to promote gene 
transfer efficiency.   
 
1.2.1.4.1 Polyethylene glycol (PEG) modified PEI 
As discussed previously, PEI/DNA complexes interact with blood components 
in vivo leading to aggregates and thus reduced the half-life and transfection 
efficacy of complexes as well as increased toxicity. To overcome this problem, 
PEG, a nonionic water-soluble polymer, was grafted to PEI to improve the 
solubility of complexes, reduce aggregation in vivo, and thus reduce 
cytotoxicity (Kichler et al., 2002; Ogris et al., 1999; Petersen et al., 2002a). 
PEG also minimizes the non-specific interaction of PEI/DNA complexes with 
proteins in the physiological fluid (Kichler et al., 2002; Ogris et al., 1999; 
Petersen et al., 2002a), which could be explained by the shielding effect of 
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PEG on the surface charge of PEI, leading to an increased blood circulation 
time. The PEG-modified PEI also allow the formation of highly concentrated 
polyplexes in contrast to non-modified PEI (Kichler et al., 2002; Tang et al., 
2003), which makes it possible to deliver high dose of DNA in a limited volume 
in vivo. For instance, intrastriatal injection into rat striatum usually uses only 
1-5 μl solution, in which enough polymer/DNA complexes should be loaded. 
On the other hand, shielding effect of PEG modification reduces the 
DNA-binding capacity of PEI and also sterically hinders non-specific 
interactions of the polyplexes with the target cells, resulting in poor transfection 
efficiency (Kichler, 2004). Thus a good strategy to graft appropriate amount of 
PEG to PEI is needed to solve this problem. Tang et al. demonstrated that by 
attaching only one or two PEG blocks to one PEI molecule dramatically 
enhanced the transfection efficiency (Tang et al., 2003). Petersen et al. also 
reported that low level of PEG grafting to PEI could increase gene delivery 
efficiency (Petersen et al., 2002a). Furthermore, PEG-modified PEI has 
generally been combined with ligand modification to improve transfection 
efficiency and to enable specific cell targeting (Kichler, 2004). 
 
1.2.1.4.2 Ligands modified PEI 
The presence of positive charges at the surface of the PEI/DNA complexes 
makes the complexes interact with plasma membranes non-specifically. Thus 
great efforts have been made to chemically incorporate cell-binding ligands 
into the PEI/DNA complexes in order to increase gene delivery specificity as 
well as transfection efficiency. Coupled covalently or non-covalently to PEI, the 
ligand targets the PEI/DNA complexes to specific cells through recognition to 
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specific cell surface receptors. For example, transferrin has been used with 
PEI to target gene delivery to proliferating cells such as tumor cells, and the 
efficiency was reported to increase up to several hundred-fold depending on 
cell type (Kircheis et al., 1997). Coupling of anti-CD3 antibody to PEI was 
reported to mediate specific gene delivery only to CD3-expressing cells 
(Kircheis et al., 1997). Coupling of epithelial growth factor (EGF) to PEI was 
also reported to target gene delivery to epithelial cells (Blessing et al., 2001).  
 
Although the incorporation of cell specific ligand improved the gene delivery 
specificity, non-specific electrostatic interactions of polymer with cell surface or 
blood components may still occur. This competition between specific 
ligand-receptor interaction and non-specific electrostatic interaction depends 
on multiple factors, such as the affinity of ligands to receptors, level of 
receptors expression on target cells, the negative charge of target cell surface 
and the amount of PEI/DNA complexes (Kircheis et al., 2001b). Therefore, 
there is still room for improving ligand-modified PEI as a vector for gene 
delivery. 
 
1.2.1.4.3 Cross-linking of PEI 
Recently another important modification of PEI is to cross-link small PEIs 
which are noncytotoxic but less efficient, by biodegradable linkages to 
enhance gene delivery efficiency while trying to minimizing cytotoxicity effects  
(Ahn et al., 2002; Petersen et al., 2002a; Thomas et al., 2005). Such linkages 
include esters, amides, orthoesters, acetals, glycosides, and disulfides. This 
approach combines the advantages of high and low MW PEIs. The hypothesis 
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put forward to explain this approach is that cross-linking will raise the 
polycation’s effective molecular weight and hence the transfection efficiency, 
while the biodegradable linkages will undergo intracellular breakdown after 
DNA delivery, hence reducing cytotoxicity (Thomas et al., 2005). Gosselin et al. 
showed that PEI 800Da conjugated with biodegradable linkages, such as 
dithiobis(succinimidylpropionate) (DSP) and 
dimethyl3,3-dithiobispropionimidate2HCl (DTBP) mediated enhanced  
transfection efficiency than non-crosslinked PEI 800Da, while maintaining 
lower toxicity than PEI 25kDa in cultured cells (Gosselin et al., 2001). Thomas 
et al. reported for their conjugates, cross-linking of branched PEI 2kDa and its 
mixture with a linear PEI 423Da via ester- and/or amide-bearing linkages, 
boosted the gene delivery efficiency of the small PEIs by 40- to 550-fold in vitro 
and 17- to 80-fold in vivo (Thomas et al., 2005). However, some other groups 
also reported that where low cytotoxicity was achieved with the conjugation, 
transfection efficiency was still far inferior to PEI 25kDa (Ahn et al., 2002; Lim 
et al., 2000; Petersen et al., 2002b). These pioneer studies suggest a possible 
way to improve PEI-meidated gene delivery for higher transfection efficiency or 
lower cytotoxicity by chemical modifications. However, many issues still 
remain at large in terms of choosing appropriate MW PEIs and biodegradable 
linkages as well as designing the degree of cross-linking, the particle size and 
the surface charge of the resulting conjugates. In addition, there is little 
information on using functional molecules such as β-cyclodextrin (CyD) in a 
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Cyclodextrins are cyclic (α-1,4)-linked oligosaccharides of α-D-glucopyranose 
containing a hydrophobic central cavity and hydrophilic outer surface.  The 
most common Cyclodextrins are α-, β- and γ-CyD, consisting of six, seven and 
eight D-glucopyranose units, respectively. Due to the lack of toxicity and 
immunogenicity, CyD has been generally used as drug carrier to deliver 
chemical drugs. CyD can also enhance solubility, bioavailability and stability of 
drugs as well as reduce odours, evaporation and haemolysis (Davis and 
Brewster, 2004). For pharmaceutical applications, CyD has been explored in 
combining with other polymers to produce cyclodextrin-containing polymers 
since 1980s, after when cross-linked structures, linear structures, pendent 
structures and tubular structures of cyclodextrin-containing polymers have 
been synthesized (Davis and Brewster, 2004). However, the use of 
cyclodextrin-containing polymers as gene delivery vectors did not begin until 
1999 (Gonzalez et al., 1999). It was reported that β-CyD modified PEI (25 kDa) 
in a pendent manner mediated higher transfection efficiency and lower 
cytotoxicity compared to unmodified PEI (Forrest et al., 2005; Pun et al., 2004). 
The enhanced transfection efficiency is possibly due to the increased uptake of 
polymer/DNA complexes after β-CyD modification (Pun et al., 2004). The 
mechanism of reduced cytotoxicity offered by β-CyD modification is still not 
very clear. However, it is speculated that β-CyD modification increased 
polymer solubility and sterically decreased non-specific binding of PEI with 
cellular components, which could reduce cytotoxicity (Pun et al., 2004). 
Hydrophobic polymers tend to have higher cell toxicity, thus through β-CyD 
modification, modified polymers generally have enhanced water solubitility 
resulting in less cytotoxicity. β-CyD molecules also sterically hinder the 
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interaction of PEI with cellular components thus reducing cytotoxicty caused 
by non-specific bindings (Pun et al., 2004). 
 
In addition, the findings that β-CyD could enhance gene delivery efficiencies of 
non-viral or viral vectors also triggered the explorations on its combining or 
modifying gene delivery vectors to promote their efficiencies, although the 
mechanism of this enhancement is still not clear yet (Arima et al., 2001; Croyle 
et al., 1998; Lawrencia et al., 2001). With these properties, it seems that 
β-CyD has a bright future in pharmaceutic industry as well as gene therapy 
applications.  
 
1.2.1.5 PEI-mediated gene delivery to tumor cells 
Brain tumor is a benign or malignant growth that occurs in the brain, originating 
from brain tissue (primary brain tumor) or from elsewhere in the body. Due to 
the complicated CNS structures and over 120 different types of brain tumors, 
conventional treatments of brain tumors such as surgery, chemotherapy and 
radiotherapy, are still far from effective. 
 
PEI, a powerful non-viral gene delivery vector, appears to have potential for 
brain tumors such as neuroblastoma, meningiomas and GBM. Studies have 
successfully shown PEI-mediated gene delivery throughout animal brains in 
both neurons and glial cells by intraventricular microinjections (Ouatas et al., 
1998), or by injections into the cerebral cortex, hippocampus and 
hypothalamus (Abdallah et al., 1996). To specifically target tumor cells, ligand 
modified PEIs were also generated for receptor mediated cell uptake. Several 
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groups reported that transferrin-PEG-PEI/DNA complexes exhibited in vivo 
brain tumor targeted reporter expression after systemic delivery (Kursa et al., 
2003; Ogris et al., 2003). Moffatt et al. reported that a peptide and PEG 
modified PEI facilitated a 12-fold increase in gene expression in tumors 
compared to expression in tumors from animals treated with the unmodified 
PEI after intravenous administration (Moffatt et al., 2005). Recently, a few 
studies have been done on PEI-mediated gene delivery for GBM both in vitro 
and in vivo. One group reported that direct intra-tumor injection of a 
siRNA-encoding plasmid targeting vascular endothelial growth factor 
complexed with linear PEI efficiently reduced the vascularization of glioma 
xenografts (Niola et al., 2006). Work of another group demonstrated that 
intratumoral delivery of an apoptosis activator gene by EGF-PEG-PEI polymer 
induced the complete regression of pre-established gliomas in nude mice, with 
no obvious adverse toxic effects on normal brain tissue (Shir et al., 2006). 
 
However, these studies on PEI non-viral vector mediated gene transfer to 
brain tumor cells did not address the issue of multidrug resistance (MDR). 
MDR is a major problem often encountered in the drug treatment of brain 
tumors such as GBM which showed a high frequency (80%) of primary 
refractoriness to chemotherapy (Rieger et al., 2000). Previous studies found 
that MDR of cancer cells could result from increased drug efflux caused by 
ATP-dependent efflux pumps, reduced drug uptake, activation of coordinately 
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ATP-dependent efflux pumps are known as a family of ATP-binding cassette 
(ABC) transporters which share sequence and structure homology. 
P-glycoprotein (PGP) and multidrug-resistance-associated protein 1 (MRP1), 
two important ABC transporters, are expressed in many human cancers. The 
expression of these transporters has been shown to correlate with drug 
response and survival. PGP, encoded by multidrug resistance gene-1 (MDR1), 
has received particular attention after PGP was discovered to play a key role in 
the drug resistance phenotype of many tumor cells by extruding xenobiotics 
from the cells (Lee and Bendayan, 2004), and is considered as the main cause 
of classical MDR phenotype (Gottesman et al., 2002). PGP is a 
broad-spectrum multidrug efflux pump that has 12 transmembrane regions and 
two ATP-binding sites. The transmembrane regions bind hydrophobic drug 
substrates that are either neutral or positively charged, and two ATP-binding 
sites provide energy needed for transport of drug molecules or re-set PGP to 
original conformation (Ramachandra et al., 1998; Sauna and Ambudkar, 2000). 
It was demonstrated that PGP expression was highly expressed in most 
neuroblastomas and meningiomas (Spiegl-Kreinecker et al., 2002), some 
malignant glioma cells as well as in endothelial cells within the gliomas (Becker 
et al., 1991; Rieger et al., 2000). MRP1 is similar to PGP in structure, with the 
exception of an amino-terminal extension that contains 
five-membrane-spanning domains attached to a PGP-like core. It was reported 
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In CNS, it is striking that ABC transporters have an important role in regulating 
normal central nervous system permeability. The blood-brain-barrier (BBB) 
has the abundant PGP expression in endothelial cells of capillaries to protect 
CNS from water-soluble toxins (Schinkel et al., 1996). MRP1 is located to the 
choroids plexus where it pumps the metablolic waste products out of 
blood-cerebrospinal-fluid (CSF) (Girardin, 2006). These gatekeepers on 
normal CNS structures further impose the difficulty of chemotherapy accessing 
the brain tumors. 
 
As currently used anticancer drugs are mostly known as PGP substrates which 
can be transported out of cells by PGP; this may account for the modest to 
poor response of tumor cells to chemotherapy. To overcome the 
chemotherapy resistance of tumor cells, many efforts have been implemented 
into developing chemical compounds that inhibit PGP function, known as PGP 
inhibitors. Many PGP inhibitors have been identified and widely used to inhibit 
PGP function and reverse MDR. These inhibitors include calcium channel 
blockers, calmodulin antagonists and antibiotics. Some PGP inhibitors such as 
verapamil are also substrates of PGP and thus work by competing with the 
chemical drugs for transport by the PGP pump (Saeki et al., 1993a; Yusa and 
Tsuruo, 1989). Other PGP inhibitors are not transported by PGP but may 
reverse MDR by blocking the initial binding of drugs to PGP (Germann, 1996; 
Saeki et al., 1993b). Chan et al. first used cyclosporine, a PGP modulator, in 
combination with chemotherapy for in retinoblastoma patients and achieved 
the relapse-free rate as high as 90% (Chan et al., 1996). Due to the high 
toxicity and unsatisfactory specificity problem of existing PGP inhibitors, the 
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effect of down-regulating PGP expression using cationic lipid-mediated 
anti-sense RNAs or viral vector-mediated small interfering RNA (siRNAs) in 
drug resistant tumor cells was also investigated. Results from these studies 
showed obvious reduced MDR1 mRNA level and PGP protein level, as well as 
enhanced sensitivity to chemical drugs (Kong et al., 2005; Wu et al., 2003; Xu 
et al., 2005; Zhao et al., 2006).  
 
In cancer therapy, non-viral vector-mediated gene therapy, as another 
promising novel therapy for drug resistant tumor cells such as brain tumors, 
may also encounter the efflux problem caused by ABC transporters which 
abundantly expressed in CNS. If it is true, the information would be useful to 
regulate non-viral vector mediated gene delivery efficiency by controlling 
expression or function of ABC transporters. However, no work has been done 
yet on this issue. Thus it motivates us to investigate the relationship between 
PGP efflux pump and PEI-mediated gene delivery in drug resistant tumor cells, 
and to explore the influence of PGP on PEI-mediated gene transfer efficiency. 
Regulating PGP expression or function in these tumor cells by using 
pharmaceutical or biological molecules was also explored in order to achieve 
optimal gene delivery efficiency. 
 
1.2.2 Viral vectors 
Although non-viral vectors have the advantages of avoiding immune response 
and offering ease of production and preparations, their relatively poor 
transgene and transient transgene expression compared to viral vectors still 
make viral vectors the dominant delivery vehicles in gene therapy field. There 
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are a lot of viral vectors being utilized for delivering genes to the CNS; these 
include adenovirus, adeno-associated virus, retrovirus and the newly emerged 
baculovirus. Currently, adenovirus, adeno-associated virus and retrovirus are 
the most common vectors used in gene therapy, although their respective 
limitations are still outstanding in applications.  
 
1.2.2.1 Adenovirus (Ad) 
Recombinant Ad are large (60-90 nm in diameter), non-enveloped particles 
with a double-stranded DNA genome of 36kb (Horne et al., 1975). Ad vectors 
are among the earliest vectors used for gene delivery in experimental animal 
brain models (Akli et al., 1993; Bajocchi et al., 1993; Davidson et al., 1993), 
and are characterized by their capabilities of yielding high titers and high level 
of gene expression. But their toxicity issue remains a major problem for their 
clinical trials (Lusky et al., 1998; Raper et al., 2003; Schiedner et al., 1998), 
with the reported death of a young male in an adenovirus gene therapy trial 
(Raper et al., 2003). 
 
1.2.2.2 Adeno-associated virus (AAV) 
AAV consists of a non-pathogenic, small virion (20-24nm in diameter) 
containing a single-stranded DNA genome which is flanked by viral inverted 
terminal repeat sequence (ITRs). AAV vectors are able to drive long-term high 
transgene expression reported as long as several years (Lebherz et al., 2005; 
Xiao et al., 1996). Our previous work showed that long-term specific and 
enhanced transgene expression in neurons could be achieved by using AAV 
with a hybrid promoter CMV E /PDGF (Wang et al., 2005). But the small 
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packaging capacity (4.5kb) and time-consuming virus preparations of AAV 
vectors limit its use as the gene delivery vector for larger genes (Rabinowitz 
and Samulski, 1998).  
 
1.2.2.3 Retrovirus 
Retroviruses are lipid enveloped particles comprising a diploid RNA genome of 
8-11kb. Retrovirus vectors, mostly derived from Moloney murine leukemia 
virus (Mo-MuLV), can intergrate their genetic material into the chromosomal 
DNA of host cells, creating the potential for long-term expression (Weber et al., 
2001). This is advantageous when long-term expression of the transgene is 
essential for the treatment of some diseases. However, this random integration 
might also activate some prooncogenes, which is highly undesirable 
(VandenDriessche et al., 2003).  
 
All the problems with these traditional viral vectors have not been solved so far, 
and therefore, the newly emerged baculovirus seems to be a promising gene 
delivery vector with its unique characteristics. 
 
1.2.2.4 Baculovirus 
Baculoviruses constitute a group of double-stranded DNA viruses that cause 
diseases of arthropods. The best studied member of the baculovirus family, 
Autographa californica multiple nucleopolyhedrovirus (AcMNPV), is a large 
enveloped virus with a double-stranded, circular DNA genome of around 
130kb. Baculovirus has been used as a conventional insecticide and a tool for 
recombinant protein expression in insect cells (Schuldt et al., 1994). The ability 
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of baculovirus to enter certain mammalian cell lines was firstly reported by 
Volkman and Goldsmith in 1983 (Volkman and Goldsmith, 1983). In 1990s, 
several groups demonstrated that recombinant baculovirus containing a 
mammalian promoter could be used to transduce some mammalian cells 
(Boyce and Bucher, 1996; Hofmann et al., 1995; Shoji et al., 1997; Yap et al., 
1997). Some other groups reported that baculovirus-mediated stable gene 
expression was achieved as well by random or site-specific chromosomal 
integration of baculovirus genome into the mammalian cell genome via 
selection or via hybrid promoter containing AAV inverted terminal repeats 
(ITRs) (Condreay et al., 1999; Merrihew et al., 2001; Palombo et al., 1998). 
Findings that baculovirus was able to efficiently transfer and express target 
genes in mammalian cells with efficiency comparable to that of adenovirus 
(Airenne et al., 2000; Kost and Condreay, 2002) opened up an avenue for 
using baculovirus as a vector in gene therapy. Recently Li Y et al. reported that 
baculovirus showed specific and high transduction efficiency of reporter gene 
in rat brain by using hybrid neuronal specific promoter, demonstrating the 
potential of baculovirus vectors for gene delivery in CNS (Li et al., 2004).  
Baculovirus is also characterized by its large cloning capacity, ease of high 
titer virus preparation, replication deficiency in mammalian cells, and the lack 
of viral gene expression in mammalian cells. These advantages suggest that 
baculovirus vectors could be a safe and efficient gene delivery vector for CNS 
diseases such as brain tumors. 
 
It has been shown that baculovirus was easily inactivated by serum 
complements when used as a gene vector for systemic delivery, which limited 
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the gene transfer by baculovirus into most organs like liver in vivo (Hofmann 
and Strauss, 1998). The CNS, protected by the BBB, however, is virtually 
isolated from circulating immunological factors including complement 
components (Carson and Sutcliffe, 1999), thus serving as a suitable organ for 
baculovirus-mediated gene delivery. Moreover, the transient gene expression 
mediated by baculovirus may also limit its application for gene therapy of 
neurodegenerative disorders which require lasting therapeutic gene 
expression. Previous studies have shown that peak levels of in vitro and in vivo 
gene expression driven by the CMV promoter placed into baculovirus vectors 
lasted for just several days and dropped quickly afterwards (Condreay et al., 
1999; Lehtolainen et al., 2002). However, in brain tumor gene therapy, in order 
to kill tumor cell more efficiently it needs high levels of therapeutic transgene 
expression in a short time rather than long time intermediate expression. Thus 
baculovirus still serves as a suitable gene delivery vector for brain tumors such 
as GBM.  
 
GBM is by far the most common and most malignant brain tumor in adults and 
is highly lethal. The mean survival time after diagnosis of GBM has remained 
unchanged during the past decade despite advances in surgical techniques, 
radiotherapy and chemotherapy. Gene therapy is thus becoming an attractive 
alternative method to treat GBM. Recently, our group reported that baculovirus 
displays a high tropism for astrocytes, displaying about 70% of the viruses 
injected into the striatum in astrocytes (Li et al., 2004), which made baculovirus 
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1.2.3 Epigenetic gene regulation by chemical compounds, histone 
deacetylase inhibitors 
Chromatin architecture is very important for gene regulation, determining 
whether a particular gene is expressed or not. In general, open chromatin 
mediates transcriptional activation due to easy access of transcription factors 
to DNA binding site, whereas condensed chromatin mediates transcriptional 
repression (Johnstone, 2002). Chromatin structure can be epigenetically 
regulated by histone acetyltransferases (HATs), histone deacetylases 
(HDACs), methyltransferases and  ATP-dependent chromatin remodeling 
protein (Johnstone, 2002). HATs acetylate lysine residues on histone tails 
inducing chromatin remodeling in an open conformation, while HDACs function 
in opposition to HATs by deacetylating lysine residues on histone tails and 
inducing chromatin condensation. Methyltransferases methylate DNA through 
recruiting HDACs, resulting in histone deacetylation and transcriptional 
repression. ATP-dependent chromatin remodeling proteins have dual roles in 
both activating and repressing transcription. The complicacy of functional 
relationships among these molecules indicates intricate regulatory processes 
are involved in turning genes on or off, and alterations in any of the molecules 
can be tumorigenic. Frequent alterations in the structure or expression of 
HATs or HDACs have been found in tumor cells. 
 
HDAC inhibitors are chemical compounds that bind to HDACs and induce 
histone acetylation by interacting with the catalytic site of HDACs, thus result in 
transcriptional reactivation of some repressed genes. Based on this, HDAC 
inhibitors have been used in adenovirus-mediated gene delivery system, 
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where HDAC inhibitors increased the expression level of coxsackie and 
adenovirus receptor (CAR) that was required for efficient adenovirus infection, 
thus increased adenoviral transgene expression (Chen et al., 2005; Kitazono 
et al., 2001; Kitazono et al., 2002; Okegawa et al., 2005). HDAC inhibitors 
have also been found to enhance gene delivery efficiency mediated by 
adeno-associated virus, whose mechanism is thought to be related to the 
proposed histone-associated chromatin form of the AAV concatemer in 
transduced cells (Okada et al., 2006). In baculovirus-mediated gene delivery 
system, HDAC inhibitors such as trichostatin A or sodium butyrate (NaB) were 
often used to further enhance the transgene expression level (Condreay et al., 
1999; Hu et al., 2003). As early as 1999, Condreay reported that trichostatin A 
improved baculovirus gene expression in mammalian cells from 10- to 100-fold 
(Condreay et al., 1999). Although the detailed mechanism of this enhancement 
is not clear yet, it is believed that it could be related to the chromatin state of 
baculovirus genome in transduced cells (Hu, 2005).  
 
HDAC inhibitors are currently being investigated as novel anti-tumor agents. 
As functional inactivation of HATs or over-expression of HDACs resulting in 
abnormalities on cell differentiation or apoptosis can mediate tumor onset and 
progression, HDAC inhibitors may exert anticancer potential by activating 
differentiation programs, inhibiting cell cycle and inducing apoptosis. Studies 
have shown that treatment of various tumor cells with HDAC inhibitors could 
induce apoptosis in vitro, and many of them also showed potent anti-tumor 
activities in vivo (Glick et al., 1999; Kwon et al., 2002; Ruefli et al., 2001; Vrana 
et al., 1999; Weidle and Grossmann, 2000). 
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As combination therapies are generally required to treat tumors in achieving 
optimal therapeutic effects, these above studies indicate a novel approach to 
use HDAC inhibitors to enhance baculovirus-mediated gene therapy by 
increasing the expression of the transgene. In addition, with their intrinsic 
anti-tumor activities, HDAC inhibitors also have the advantage to kill tumor 
cells more effectively in vitro and in vivo. Thus combination of 
baculovirus-mediated gene therapy with HDAC inhibitor seems to be a good 
approach to treat GBM.  
 
1.3 Objective of this study  
As reviewed above, chemical compounds have been utilized in development 
of gene delivery vectors for the past decades, especially in non-viral vectors 
where the most important non-viral vectors, synthetic polymers, are chemical 
compounds. Furthermore, various chemical modifications on polymers have 
been implemented to improve their gene delivery efficiencies. In cancer 
chemotherapy, common chemical drugs have been used in combination with 
anticancer drugs to improve drug delivery efficiency, which confers us to 
investigate their possible applications in non-viral gene delivery system. 
Moreover, epigenetic regulations by chemical compounds are also under trials 
recently to improve gene delivery efficiency. It seems that chemical 
compounds are opening a new wave of modifications for gene delivery 
systems, and are representing exciting prospects for a more rational approach 
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Therefore, the purpose of this study was to explore the possibility of using 
commonly available chemical drugs to improve gene delivery efficiency of 
PEI-based non-viral vectors and baculovirus-based viral vectors in CNS 
through modifications or combinations, with the aim of achieving optimal 
therapeutic effects for future applications in CNS diseases. 
 
The first part of this study was to evaluate the effectiveness of a novel 
copolymer PEI 600-CyD, which was generated by modifying low MW PEI 
600Da with a chemical drug carrier β- CyD, as a non-viral vector in CNS. The 
copolymer PEI 600-CyD was tested for transgene expression in vitro and in 
vivo, by using PEI 600Da and PEI 25kDa as controls. Cytotoxicity of 
PEI600-CyD was also evaluated compared to PEI 600Da and PEI 25kDa in 
vitro.  
 
The second objective of this study was to investigate the effect of PGP 
expression on PEI-mediated gene delivery efficiency and to explore the 
possibility of improving the gene delivery efficiency by regulating the PGP 
expression or function with pharmaceutical or biological molecules. We 
examined the possibility of PEI/DNA complexes to be PGP substrates, and 
further explored the effect of PEI-mediated luciferase gene expression after 
using a PGP inhibitor or siRNAs targeting MDR1 in the PGP-positive tumor 
cells.  
 
The third objective was to investigate the effect of HDAC inhibitors on 
baculovirus-mediated gene delivery efficiency in malignant glioma cells, and to 
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explore the feasibility of combining baculovirus gene therapy with HDAC 
inhibitor treatment to achieve enhanced therapeutic effects for brain gliomas in 
vitro and in vivo. NaB was used as a HDAC inhibitor candidate, and 
baculovirus vector containing wild type p53 (wtp53) was used to treat p53 
deficient glioma cells.  
 
This thesis explored two typical examples of gene delivery vectors, PEI-based 
non-viral vector and baculovirus-based viral vector, in CNS and investigated 
the potential approaches to improve their gene transfer efficiency by using 
simple chemical compounds. The results should contribute to a better 
understanding of the modification of gene delivery vectors and represent a 
practical way to improve their gene transfer efficiency. The results might be 
useful in providing modified gene delivery vectors for potential applications in 
treatments of CNS diseases such as neurodegenerative diseases and brain 
tumors. For the present work, we focused mainly on the gene delivery 
efficiency of the modified vectors. In future, further modification should also be 
included to obtain more powerful vectors with other improved characters such 
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2.1 Introduction 
The concept of gene therapy for neurodegenerative diseases is highly 
attractive in view of its enormous potential in improving the quality of life, 
especially for the aging population. Extensive research has been done on 
gene delivery to CNS, using either viral or non-viral vectors (Costantini et al., 
2000). Gene delivery to the CNS has proven to be challenging by its limited 
access due to the skull and the blood brain barrier, and also by its high 
vulnerability to injury, especially neurons which are very sensitive to 
environmental change. Thus choosing safe gene delivery vectors and gene 
delivery routes are very important for CNS gene therapy applications.  
 
Non-viral gene delivery systems based upon polymer/DNA complexes have 
gained increasing attention for their features of inducing relatively low toxicity 
and nearly no immune responses. Different from commonly used viral vectors, 
polymer vectors can be administered repeatedly in order to achieve long-term 
expression of transgenes when needed (Shi et al., 2003). This is fairly practical 
in treating neurodegenerative diseases where sustained satisfactory 
therapeutic gene expression is required, which single gene delivery treatment 
may not be able to achieve. Other advantages of polymer gene delivery 
systems include capability of dealing with large DNA plasmids, simplicity in 
preparation, flexibility in use and cell-type specificity after chemical conjugation 
of a targeting ligand (Davis, 2002).  
 
Among the polymers, PEI is the most powerful one which has been extensively 
studied and shown high transfection efficiency both in vitro and in vivo 
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(Godbey et al., 1999a; Kichler, 2004; Lungwitz et al., 2005; Neu et al., 2005). 
The distinguished high transfection efficiency of PEI is attributed to its strong 
pH buffering capacity which results in endosomolysis and successful 
polymer/DNA complexes release into the cytosol.  
 
In particular, PEI polymers, especially those with molecular weight of 25kDa or 
higher, may mediate intracellular DNA delivery and transgene expression in 
terminally differentiated non-dividing neurons (Abdallah et al., 1996; Boussif et 
al., 1995; Goula et al., 1998; Shi et al., 2003). After direct brain injection, 
PEI/DNA complexes can reach the transgene expression levels comparable to 
those obtained with the lentivirus or adenovirus vectors (Abdallah et al., 1996). 
However, depending on molecular weight, structure and doses, PEIs can be 
toxic to certain cells, including neurons and other cells in the nervous system. 
High MW PEI polymers induce rapid necrotic-like changes resulting from 
perturbation of the plasma membrane, followed by activation of 
mitochondria-mediated apoptosis (Moghimi et al., 2005). In particular, 
branched PEIs with high molecular weight have displayed relatively high 
cytotoxicity, possibly due to formation of large aggregates on cell surface 
(Fischer et al., 1999; Godbey et al., 1999b; Godbey et al., 1999c). Because 
PEI may enter cell nucleus, the accumulation of non-biodegradable and highly 
positively charged PEI in the cell nucleus is also a concern for its long-term 
effects on cellular gene expression (Godbey et al., 1999c; Godbey et al., 2001). 
Thus, extensive efforts have been made to modify high MW PEI polymers in 
recent years in order to improve their biocompatibility by modifying the solubility, 
biodegradability and chemical homogeneity of the polymers (Kichler, 2004; 
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Lungwitz et al., 2005; Neu et al., 2005). As low MW PEIs (< 2000 Da) displayed 
much less toxicity but almost no transfection efficiency (Fischer et al., 1999), 
several groups have tried to link low MW PEI blocks to develop degradable 
and biocompatible gene delivery polymers (Ahn et al., 2002; Gosselin et al., 
2001; Petersen et al., 2002). Improved transfection efficiency was achieved by 
the linked polymers in these studies.  
 
Cyclodextrins, cyclic oligomers of glucose, that can form water-soluble 
inclusion complexes with small molecules and portions of large compounds, 
have drawn people’s attention. Cyclodextrins have outstanding properties 
such as increasing drug aqueous solubility and stability. With hydrophilic cavity 
exteriors and hydrophobic cavity interiors, cyclodextrins such as β-CyD are 
commonly used as drug carriers in the past decades. CyD-containing 
polymers have been synthesized for pharmaceutical applications to improve 
drug formulation, controlled release, drug distribution and pharmacokinetic 
half-life (Davis and Brewster, 2004). Till 1999, a CyD-containing polymer was 
reported to deliver DNA into cells (Gonzalez et al., 1999), which opened a 
window for a new class of polymers as non-viral vectors.  
 
In this study, we tested our newly developed copolymer in which PEI polymers 
with MW 600Da were linked with β-CyD, for the feasibility of using this 
copolymer as a vector for gene transfection in cultured neurons and in the 
CNS after intrastriatum and intrathecal injection.  
 
2.2 Materials and Methods 
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2.2.1 Materials 
Polyethylenimine (PEI, MW 600 or 25 000 Da), β -CyD (MW 1135), 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT), cell 
culture media and fetal bovine serum (FBS) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). PEI 25kDa was purified through dialysis in three 
changes of a 100-fold volume excess of water, lyophilized, and re-hydrated 
before use. 1,1_-Carbonyldiimidazole (CDI) was from Pierce (Rockford, IL, 
USA). Luciferase activity assay kits were obtained from Promega (Madison, 
WI, USA). The protein assay kit was from Bio-Rad Labs (Hercules, CA, USA).  
 
2.2.2 Preparation of PEI600-CyD copolymer  
PEI600-CyD copolymer was a kind gift from Dr. Tang Guping and was used as 
gene delivery vector in this study. Briefly, β-Cyclodextrin (0.42 g, 0.37 mmol) 
and 1,1’-carbonyldiimidazole(CDI) (0.80 g, 5.2 mmol) were dissolved in 6 ml 
N,N-dimethylformanide (DMF). The mixture was stirred at room temperature 
for 1 hr under nitrogen and then precipitated in cold diethyl ether. The resulting 
CyD-CDI was filtered, dissolved in 5 ml dimethyl sulfoxide (DMSO) and stored 
at 4°C. PEI 600 (1.5 g) was dissolved in 3 ml DMSO. The described CyD-CDI 
in 5 ml DMSO and 0.3 ml triethylamine (Et3N) were added dropwise to the PEI 
solution over 1.5 hr with stirring, followed by additional 5 hr reaction. After the 
reaction, the mixture was dialyzed in water for 2 days and freeze-dried for 
another 2 days.  
 
2.2.3 Reporter plasmid and polymer /DNA complexes  
 31
Chapter 2. Low Molecular Weight Polyethylenimines Modified by β-Cyclodextrin 
for Improved Gene Delivery   
The firefly luciferase reporter plasmid used was pCAGluc (kindly donated by 
Yoshiharu Matsuura, National Institute of Infectious Diseases, Tokyo, Japan), 
with a composite promoter CAG consisting of the cytomegalovirus 
immediate-early enhancer, chicken β-actin promoter and rabbit β-globin 
polyadenylation signal. Plasmids were complexed with the above copolymer, 
as well as PEI polymers (MW= 600Da or 25kDa) for gene transfection.  
 
2.2.4 MTT cytotoxicity assay 
Neuronally differentiated human NT2 cells and mouse C17.2 cells were used. 
The cells (1 × 105 cells /well) were seeded into 96-well microtiter plates. After 
overnight incubation, the culture medium was replaced with 100 μl of serial 
dilutions of polymer solutions prepared in serum supplemented tissue culture 
medium and the cells were cultured for another 24 hr. A volume of 20 μl filtered 
MTT stock solution in phosphate-buffered saline (PBS, 5 mg/ml) was added to 
each well to reach a final concentration of 0.5 mg MTT/ml. After 4 hr, 
un-reacted dye was removed by aspiration. The crystals were dissolved in 100 
μl /well DMSO and measured spectrophotometrically in an ELISA reader 
(Model 550, Bio-Rad) at a wavelength of 595 nm. Cell growth (%) relative to 
control cells in cell culture medium without polymers was calculated by 
absorbance in test/ absorbance in control×100%. 
 
2.2.5 Gene transfection assay 
For in vitro transfection studies, cells were seeded 24 hrs prior to transfection 
into a 24-well plate (Becton-Dickinson, Lincoln Park, N.J.) at a density of 5×104 
per well with 0.5 ml of the indicated medium. At the time of transfection, the 
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medium in each well was replaced with 300 μl of Opti-MEM containing PEI 
600Da/DNA, PEI 25kDa/DNA or PEI600-CyD/DNA complexes at indicated PEI 
nitrogen per DNA phosphate (N/P) ratios. For each well, 0.5 μg DNA was used. 
After incubation for 3 hr at 37°C, the medium was replaced with 0.5 ml of fresh 
complete cell culture medium and cells were further incubated for 24 hr. 
 
For in vivo studies, polymer /DNA complexes were injected into either the rat 
striatum or into the lumbar subarachnoid space. For injection into striatum, rats 
were anesthetized by an intraperitoneal injection of sodium pentobarbital (60 
mg/kg of body weight) and positioned in a stereotaxic instrument with the nose 
bar set at 0. DNA/PEI complexes were separately, bilaterally injected into the 
striatum at two injection points. The ranges of coordinates from bregma and 
dura were: anterior (A), -1.0~+1.0 mm, lateral (L), +2.0~+3.0mm or 
-2.0~-3.0mm, ventral (V), –5.0 mm. A volume of 5 μl of the complexes 
containing 1 μg DNA was used in each injection. The rate of injection was 1 
μl/min and the needle was allowed to remain in situ for 5 mins before being 
slowly retracted at the end of each injection. The intrathecal lumbar injection 
was done using a 10 μl micro-syringe connected with a 26-gauge needle, after 
the skin around L4-L5 was exposed. The slight movement of the tail indicated 
the proper injection into the subarachnoid space. For each rat, 20 μl of 5% 
glucose solution containing 4 μg of plasmid DNA complexed with polymers 
were given by two injections. After a slow injection of 10 μl of polymer DNA 
complexes over 2-5 min, the syringe was left in place for 5 min to limit diffusion 
of the DNA from the injection site owing to the backflow pressure. 
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To examine gene expression, cells or tissues were collected and homogenized 
in a cell lysis buffer (Promega, WI, USA). Luciferase activities in extracts were 
measured using a luciferase assay Kit (Promega WI, USA) on a single-well 
luminometer (Berthold Lumat LB 9507, Germany) for 10 sec. The relative light 
units (RLU) were normalized against protein concentration in the cell extracts, 
which was measured using a protein assay kit (Bio-Rad). Luciferase 
expression data were analyzed statistically with the Student’s t test. 
 
For immunostaining, anesthetized rats were sacrificed at 2 days post-injection 
by intracardiac perfusion with Ringer’s solution followed by 2% 
paraformaldehyde in 0.1 M PBS (pH 7.4). Dorsal root ganglions (DRGs) at 
L4-6 were removed and post-fixed in the same fixative agent for 2-4 hours 
before being transferred into 0.1 M PBS containing 15% sucrose. Frozen 
sections were cut at 30 μm thickness and incubated overnight with a polyclonal 
anti-luciferase antibody (Promega, WI, USA; dilution 1:150) or a monoclonal 
antibody against NeuN (Chemicon International, USA; dilution 1:500), followed 
by the secondary antibody incubation using anti-rabbit IgG Tritc conjugate 
(Sigma-Aldrich, dilution 1:100) or anti-mouse IgG FITC conjugate 
(Sigma-Aldrich; dilution 1:100) for 1 hour. The processed sections were 
examined with an Olympus 500 confocal laser scanning microscope. Each 
section was initially scanned with a 488 nm laser line, and an emission filter BP 
510-525, for the detection of FITC fluorescein; and with a 543 nm laser line, 
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2.3 Results 
2.3.1 Effects of PEI600-CyD copolymer on cell survival  
Along with our main goal to improve the biocompatibility of higher MW PEI 
polymers, we set up to investigate effects of the PEI600-CyD copolymers on 
cell survival in neurons, a cell type highly susceptible to assaults (Figure 2.1). 
Human NT2 and mouse C17.2 neurons were exposed to various 
concentrations of the copolymer as well as PEI polymers for 24 hr and then 
assessed by MTT assay. The cell viability assay indicated that the copolymer 
exhibited much lower cytotoxicity in the neurons than PEI 25kDa. At the 
concentration of 1 μM, cell viability was 100% in NT2 human neurons and 75% 
in C17.2 mouse neurons when PEI600-CyD or PEI 600 was used, whereas all 
neurons died in the PEI 25kDa test groups at this concentration (Figure 2.1). 
With further increase of concentration to 4 μM, NT2 neurons still exhibited 90% 
cell viability and C17.2 neurons exhibited 60-70% cell viability when 
PEI600-CyD and PEI 600 polymer used (Figure 2.1). The results suggest that 
the copolymer formed maintain the desirable property of low cytotoxicity 
displayed by lower molecular weight PEI polymers.   
 
2.3.2 Gene expression mediated by PEI600-CyD copolymer in vitro 
To examine the possibility of using the PEI600-CyD copolymer as a non-viral 
gene delivery vector, we first investigated the gene expression of 
copolymer/DNA complexes in cell cultures. A plasmid with a luciferase reporter 
gene under the control of the CAG promoter were used for gene transfection 
efficacy assessment in cultured human NT2 and mouse C17.2 neurons in 
24-well plates (Figure 2.2). For each well, 0.5 μg DNA was complexed with 
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polymer at indicated N/P ratio. The luciferase expression levels increased 
significantly when PEI600-CyD was used instead of the low MW PEI polymers, 
being several hundred to thousand times higher, depending on N/P ratio tested. 
In both types of neurons, the transfection efficiencies with the PEI600-CyD 
copolymers were comparable to those provided by PEI 25kDa at relatively 
lower N/P ratios (N/P of 5, 10). At higher N/P ratios (N/P of 15, 20), 
PEI600-CyD performed even better than PEI 25kDa in NT2 neurons (Figure 
2.2).  
 
2.3.3 Gene expression mediated by PEI600-CyD copolymer in vivo  
We further tested PEI600-CyD copolymer-mediated gene transfer in rat brain 
(Figure 2.3) and lumbar subarachnoid space (Figure 2.4&2.5). We injected 
PEI600/DNA complexes, PEI 25kDa/DNA complexes or PEI600-CyD/DNA 
complexes containing 1μg of DNA into rat striatum. Polymer/DNA complexes 
were prepared at different N/P ratios. Two days after polymer/DNA complexes 
injection, brain tissues were collected for luciferase activity assay. Results 
showed that the gene expression mediated by PEI 600 was at background 
level (data not shown), whereas PEI600-CyD mediated reporter gene 
expression was obviously very much higher, indicating the greatly enhanced 
gene transfer efficiency (Figure 2.3). However, the gene expression mediated 
by PEI600-CyD was still lower than that mediated by PEI 25kDa (Figure 2.3). 
Even at N/P ratio of 10 where PEI600-CyD showed the highest expression 
level, PEI 25kDa still showed 1.5 times greater expression level than 
PEI600-CyD (Figure 2.3). 
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We also injected the different polymer/DNA complexes into the rat lumbar 
subarachnoid space and studied luciferase gene expression in the spinal cord. 
After intrathecal injection, PEI600-CyD improved transfection efficiency in the 
spinal cord. PEI600-CyD improved transfection efficiency in the spinal cord by 
2.5- to 3.5- fold over PEI 600 at N/P ratios of 10 and 15 (Figure 2.4). These 
levels of transgene expression were rather close to that provided by PEI 
25kDa (Figure 2.4). 
 
To further determine the transgene expression in spinal cord after intrathecal 
injection of PEI 600-CyD/DNA complexes, immunostaining was done to locate 
the transgene expression in cells. Cryostat sections of the lumbar spinal cord 
were collected after intrathecal injection and stained using antibodies against 
luciferase and different cell markers. Similar to that observed in our previous 
study using PEI 25kDa/DNA complexes (Shi et al., 2003), luciferase 
expression was observed in neuroectodermal cells as well as glial cells. As an 
example shown in Figure 2.5, colocalization of luciferase expression and 
neuronal marker expression indicated that expression of the transgene in 
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Figure 2.1 Cell viability assays of PEI 600-CyD in NT2 (A) and C17.2 (B) 
neurons. Cell viability was determined by a MTT assay and expressed as 
percentage of the control, i.e. the untreated cultures. The data shown here are 
representative of two to three independent experiments. 
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Figure 2.2 Transfection efficiency of PEI600-CyD in NT2 (A) and C17.2 (B) 
neurons. The cells were treated with 0.5 μg of pCAG-luc plasmid complexed 
by PEI 600, PEI600-CyD or PEI 25kDa in serum-free medium for 24 hr in 
24-well plates. Results are expressed in RLU/mg protein (mean± SD, n = 6). 
***p < 0.001, compared with PEI600; ++p < 0.01, compared with PEI 25kDa. 
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Figure 2.3 Luciferase activity quantifications after injection of pCAG-luc 
plasmid complexed by PEI600-CyD or PEI 25kDa into the rat striatum. The 
tissues samples were collected 48 hr later for luciferase activity assays. 
Results are expressed in RLU per mg tissue protein. Four rats were used per 
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Figure 2.4 Luciferase activity quantifications after intrathecal injection of 
pCAG-luc plasmid complexed by PEI 600, PEI600-CyD or PEI 25kDa. The 
tissues samples were collected 48 hr later for luciferase activity assays. 
Results are expressed in RLU per mg tissue protein. Four rats were used per 
group and values are presented as means ± SD. *p < 0.05 and **p < 0.01, 
respectively, compared with PEI 600.  
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Figure 2.5 Confocal scanning microscopy images of luciferase expression in 
spinal neurons after intrathecal injection of pCAG-luc plasmid complexed by 
PEI600-CyD. Frozen sections of rat lumbar spinal cord collected 2 days after 
injection of PEI 600-CyD/DNA complexes at an N/P ratio of 15 were used for 
double immunostaining against Luc to show transfected cells and against 
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2.4 Discussion  
PEI has been known to be an efficient gene carrier with the highest cationic 
charge potential. High transfection efficiency of PEI, along with its cytotoxicity, 
strongly depends on the molecular weight. Recently great effort has been 
made to develop biocompatible polymers based on low MW PEIs. Kim and his 
colleagues reported copolymers of low MW PEI and PEG connected with 
biodegradable linkages (Ahn et al., 2002). Hydrophilic PEG is expected to 
reduce the toxicity of the copolymer, improve the poor solubility of the PEI and 
DNA complexes. It should also help to introduce degradable bonds by reaction 
with the primary amines in the PEI. Therefore, high transfection efficiency was 
obtained from an increased MW of the copolymer. And low cytotoxicity was 
obtained from the introduction of PEG and the degradation of the copolymer 
into low MW PEIs (Ahn et al., 2002). Gosselin et al cross-linked low MW PEIs 
via reversible disulfide bonds. The cross-linked PEI mediated 2-fold less gene 
expression than PEI 25kDa, but exhibited less toxicity to cultured cells 
(Gosselin et al., 2001). Kissel’s group developed a gene transfer vector 
synthesized by linking low MW PEI blocks using an oligo (L-lactic 
acid-co-succinic acid), which was soluble in water and degraded via 
base-catalyzed hydrolytic cleavage of amide bonds. The copolymer showed a 
significant enhancement of transfection activity as well as exhibited a low 
toxicity profile (Petersen et al., 2002). In addition, Pack’s group has developed 
a biodegradable analogue of PEI 25kDa by addition of PEI 800Da to small 
diacrylate cross-linkers (Forrest et al., 2003). In cell transfection studies, the 
polymer provided gene expression levels 2- to 16-fold higher than PEI 25kDa. 
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This is probably the only such biodegradable polymer that has shown in vitro 
gene delivery activity greater than that of commercial PEI 25kDa.  
 
Many issues still remain in terms of how to design effective and biodegradable 
gene delivery polymers. There is little knowledge on using a functional 
backbone to cross-link polycation to form a gene delivery vector. As such, 
cyclodextrins such as β-CyD came to our attention.  
 
The lack of toxicity and immunogenicity of  cyclodextrins has been well 
documented (Davis and Brewster, 2004). Taking full advantage of the ability of 
cyclodextrins to form inclusion complexes with a variety of guest molecules in 
solution and in solid state, they have been used as drug carriers to improve the 
solubility, stability and bioavailability of chemical drugs (Davis and Brewster, 
2004). Cyclodextrins can disrupt biological membranes by forming complexes 
with phospholipids and cholesterols. When being used together with either 
viral or non-viral gene carriers, cyclodextrins could enhance gene transfer 
efficiency of the carriers (Arima et al., 2001; Croyle et al., 1998; Lawrencia et 
al., 2001). The mechanism underlying the improved gene delivery is not clear. 
It was indicated that cyclodextrins enhanced adenoviral-mediated gene 
transfer probably by permeabilizing the cell membrane (Croyle et al., 1998). 
Additional studies will be necessary to explore whether this 
membrane-permeabilizing effect can assist cell take-up and intracellular 
trafficking of plasmid DNA. 
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Davis’s group published the first report of using CyD polymers for the delivery 
of nucleic acids, in which β-CyD was modified to contain amines and served as 
part of the backbone of linear polymers (Gonzalez et al., 1999). Since then, 
several other types of CyD-containing polymers have been developed for gene 
delivery, many of which are CyD pendent polymers having a polycation 
skeleton (Davis and Brewster, 2004; Gonzalez et al., 1999; Hwang et al., 
2001). For example, PEI 25kDa has been used as a polymer backbone to link 
β-CyD pendent moieties (Forrest et al., 2005; Pun et al., 2004). In addition to 
offering satisfactory efficiency in mediating gene transfection, these 
β-CyD-modified polycations usually display lower toxicities when compared 
with their non-modified counterparts. However, other concerns related to high 
MW PEI such as their effects on gene expression and metabolic activity still 
remain since there is neither a degradation pathway nor a mechanism of 
excretion for high MW PEI polymers (Fischer et al., 1999). Therefore, the use 
of a less toxic, low MW PEI may improve the biocompatibility further.  
 
In the present study, we reported the gene delivery efficiency of our newly 
developed PEI600-CyD polymer as a non-viral vector. PEI600-CyD polymer is 
synthesized by linking low MW PEI polymers with difunctionalized cyclodextrin 
to form a cationic copolymer. The copolymer has several attractive features, 
which make it suitable as a gene delivery vector.  
 
Low cytotoxicity of PEI600-CyD copolymer 
The PEI600-CyD copolymer seems biocompatible to be used in the nervous 
system, showing no toxicity to the neurons tested in this study. This is strikingly 
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different from PEI 25kDa, which causes cell death of neurons at low doses. At 
concentration higher than 0.5 μM, when PEI600-CyD copolymer or PEI 600 
showed most cells viable (>75%), PEI 25kDa exhibited almost no cell survival 
(Figure 2.1). It seems that the copolymer retains the low cytotoxicity 
characteristics of PEI 600 and CyD. In addition, the PEI600-CyD copolymer is 
degradable in physiological condition. The degradation products of the 
copolymer are low MW PEI and CyD, which are presumably relatively easier to 
be excluded out of the cell nucleus and the cytoplasm, and be eliminated from 
the body. Even though the low MW PEI polymers may still remain inside the 
cell and interact with cellular organelles, they should have less pronounced 
effects on cell functions. This is again significantly different from 
non-degradable PEI 25kDa.  
 
Enhanced transfection efficiency by PEI600-CyD/DNA complexes 
The copolymer mediates gene expression efficiently in cultured neurons, with 
much higher transfection efficiency than that mediated by unmodified PEI 600 
and close to that offered by PEI 25kDa. Even in a harsh environment such as 
rat subarachnoid space, the copolymer still exhibits comparable gene delivery 
efficiency to PEI 25kDa. This result is consistent with previous reports where 
CyD was used to modify PEI 25kDa and increased transfection efficiency was 
found after modification (Forrest et al., 2005; Pun et al., 2004). The 
PEI600-CyD copolymer reported here has a net positive charge. Positively 
charged groups include primary, secondary and tertiary amines that may 
efficiently bind and condense plasmid DNA. Also the copolymer appears to be 
able to disrupt endosome membranes once endocytosed into cells and 
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promote the endosome escape or release of DNA molecules, which promotes 
transfection efficiency. 
 
Repeated gene delivery in vivo 
Transient expression of plasmid DNA is a disadvantage of non-viral gene 
delivery system in treating many of degenerative disorders with slow 
pathogenesis, including neurological diseases. The low toxicity and 
immunogenicity of the copolymer tested in the current study raises the 
possibility of repeated injection of DNA complexed by the polymer to achieve 
long-term gene expression.  
 
As CNS is difficult to be accessed and also very vulnerable to injury, it is 
important to establish a relatively safe delivery route to carry out repeated 
gene transfer. Our in vivo study demonstrated two delivery routes, direct 
injection into brain tissue locally and lumbar intrathecal injection to the CSF. 
The former localizes the transgene expression in injection site, and is quite 
invasive and thus seems not practical for repeated gene transfers. In this study, 
even with a single injection, our copolymer still exhibited lower gene delivery 
efficiency than PEI 25kDa, which could possibly be due to the invasive delivery 
route resulting in brain damage or hemorrhage that affected gene expression. 
It may not be a good choice for repeated injections. To attain repeated CNS 
delivery, a cannula could be implanted into brain and connected to a 
subcutaneous reservoir that confers continuous infusion of a therapeutic gene 
(Imaoka et al., 1998; Jackson et al., 2001). The lumbar injection, as a routine 
and relatively non-traumatic clinical practice to the CSF, is a less invasive 
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route that makes multiple administrations feasible. Due to the relatively wide 
subarachnoid space at the site and the mobility of nerves within the CSF, 
lumbar puncture imposes little damage to the spinal cord. It was also 
demonstrated that there is relatively prevalent transgene expression in the 
CNS by lumbar injection (Imaoka et al., 1998; Martino et al., 2001; 
Meuli-Simmen et al., 1999; Ram et al., 1994). Tang et al. and Shi et al. 
reported that after lumbar injection, PEI-mediated gene expression could be 
detected up to the brain stem (Shi et al., 2003; Tang et al., 2003). These work 
all indicate that this delivery route is ideal in treating certain diseases such as 
neurodegenerative disorders and spinal cord trauma, which require repeated 
administration of drugs. 
 
In addition to these delivery routes, it has also been indicated that 
intramuscular injection could be another delivery route without much 
destruction of the CNS, as neurons are capable of taking up exogenous 
particulates from the muscles that they innervate. Wang et al. reported that 
after peripheral intramuscular injection of plasmid DNA complexed with the 
PEI in the rat hypoglossal system, transgene expression could be detected in 
hypoglossal motor neurons in the brain stem, demonstrating that PEI/DNA 
complexes had migrated by retrograde axonal transport to neuronal cell bodies 
in the brain stem after being internalized by nerve terminals in the tongue 
muscle (Wang et al., 2001). 
 
Shi et al. reported that with repeated lumbar injection of PEI/DNA polymers, a 
70% attenuation of gene expression could be observed after the rejection. 
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Using PEG-grafted PEI for DNA complexes, no attenuation of gene expression 
was detected after repeated intrathecal injections. The mechanism of this 
inhibitory effect is not resolved yet. One possibility is the poor solubility of PEI 
and the toxic effects caused by aggregation or precipitation of PEI/DNA 
complexes, as suggested in the finding that the higher the N/P ratio is, the 
stronger the inhibitory effects is. PEG grafting can provide improved solubility 
of macromolecules and reduce the aggregation of particulates, thus reduce the 
inhibitory effect. Our copolymer that is synthesized by low MW PEI and CyD 
has a good solubility and may circumvent this attenuation effect and make 
repeated gene delivery more feasible.  
 
As for in vivo application, another obstacle is the specificity, which underscores 
the importance of restricted transgene expression in particular target cells, 
thereby limiting side effects in non-target cells. Our study showed that 
copolymer-mediated gene expression by lumbar injection was observed in 
neurons as well as glial cells. Therefore, further modification of the copolymer 
is needed in gene therapy for specific diseases; coupling ligands to the 
delivery vector could achieve this. 
 
Based on the above findings, although more investigations would be 
necessary to promote its in vivo application, our PEI600-CyD copolymer could 
be a safe as well as an effective delivery system of therapeutic genetic 
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3.1 Introduction 
Gene therapy is emerging as a modern medical intervention for the treatment 
of a variety of disorders, including malignancies. The approach involves the 
delivery of therapeutic genes and their expression in target cells. Many viral 
gene vectors have been used for delivering genes into tumor cells. However, 
possible side effects such as induction of immunological and pathogenic 
complications have limited the widespread use of these viral vectors. Non-viral 
gene delivery systems based upon polymer/plasmid DNA complexes are 
emerging as a viable alternative for their potential in avoiding problems 
inherent to viral gene vectors. Non-viral vectors, especially polymers, show 
significantly low safety risks and can be tailored to specific therapeutic needs 
by choosing appropriate molecular weights or coupling of cell or tissue specific 
targeting moieties with chemical conjugations. Other prospective advantages 
of polymer gene delivery vectors also include capability of dealing with large 
DNA molecules, simplicity in preparation and flexibility in use. These plasmid 
DNA-based systems closely resemble traditional pharmaceuticals, as they can 
be produced in large quantities with high reproducibility and low cost, stored 
stably at room temperature, and administered easily and repeatedly to 
patients. 
 
In cancer gene therapy, although cancer cells are known to be difficult to 
transfect, non-viral vectors such as cationic lipids and cationic polymers have 
shown to be able to deliver genes into cancer cells. It has been reported that 
liposomal delivery of herpes simplex virus thymidine kinase (HSV-tk) gene 
combined with ganciclovir treatment induced glioma cell death (Yoshida et al., 
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2001; Zerrouqi et al., 1996). Shi et al. also demonstrated that intratumoral 
injection of cationic lipid-mediated interleukin-12 caused tumor regression in a 
mouse tumor model (Clark et al., 2000). However, variable formation, 
biological instability and poor bio-distribution have limited cationic lipids for 
further applications (Pedroso de Lima et al., 2001).  
 
On the other hand, cationic polymers especially synthetic PEI have shown 
some promise. PEI has been extensively studied and shown high transfection 
efficiency both in vitro and in vivo in various types of cells (Boussif et al., 1995). 
Slow delivery of PEI/DNA complexes into tumors using a micropump produced 
a high and long-lasting expression of transgenes, although direct injection with 
a syringe was not successful (Coll et al., 1999). Distributed transgene 
expression was observed in disseminated cancer cells after intraperitoneal 
delivery of PEI/DNA complexes into the peritoneal cavity of mice, without 
significant cytotoxicity (Aoki et al., 2001). Ligands such as transferrin, EGF, or 
specific peptide were conjugated to PEI and these conjugations exhibited 
tumor-specific gene expression in vivo (Kursa et al., 2003; Moffatt et al., 2005; 
Ogris et al., 2003). More recently, therapeutic siRNA or double stranded RNA 
complexed with ligand-modified PEI was also reported to be delivered into 
glioma cells and to exert anti-tumor effects in vitro and in vivo (Grzelinski et al., 
2006; Shir et al., 2006). SiRNAs are a class of 20-25 nucleotide-long 
double-stranded RNA molecules which play an important role in interfering 
with the expression of a specific gene. After introduced into cells, siRNA can 
target mRNA of the particular gene based on sequence complementarity and 
thus specifically diminish or abolish the gene expression. These studies all 
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demonstrate that PEI is a powerful non-viral gene delivery vector with strong 
potential for cancer gene therapy such as brain tumor gene therapy. However, 
when compared to viral vector, the transfection efficiency of non-viral vector in 
tumor cells in vivo is still very low. 
 
For cancer cells, one problem we cannot overlook is their resistance to 
anti-cancer drugs. Cancer cells have developed the capability of being 
resistant to a variety of cytotoxic drugs, a condition termed MDR. The detailed 
mechanisms of MDR have not been well established, although there are 
several factors which could account for it (Gottesman et al., 2002). MDR can 
result from increased drug efflux by ATP-dependent efflux pumps which 
belong to a family of ABC transporters (Ambudkar et al., 1999). MDR can be 
conferred by reduced drug uptake (Shen et al., 2000) or by the activation of 
coordinately regulated detoxifying systems such as DNA repair and the 
cytochrome P450 mixed-function oxidases (Gottesman et al., 2002). MDR can 
also be mediated by defective apoptotic pathways as a result of malignant 
transformations such as p53 mutation (Lowe et al., 1993).  
 
Among these factors, MDR has been attributed mainly to the over-expression 
of  PGP, a member of the ABC transporters, to extrude therapeutic agents out 
of cells (Germann, 1996). PGP is a 170 kDa plasma membrane protein, 
encoded by the MDR1 gene. PGP contains 12 transmembrane regions and 
two ATP-binding sites. Many structurally and functionally unrelated molecules 
have been identified as substrates for transport by PGP, including drugs, 
antibiotics, fluorescent dyes, steroids, and cyclic and linear peptides. As 
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currently used anticancer drugs are mostly known as PGP substrates and they 
can be transported out of cells by PGP, it may account for the modest to poor 
response to chemotherapy in cancer cells. These drugs include the vinca 
alkaloids such as vincristine, the anthracyclines like doxorubicin, the RNA 
transcription inhibitor actinomycin-D, and the microtubule-stabilizing drug 
paclitaxel (Ambudkar et al., 1999).  
 
To overcome the drug resistance of cancer cells, strategies which focus on 
increasing chemotherapy sensitivity through decreasing expression or 
inhibiting functional activity of PGP have been developed in the clinic. The 
most commonly used agents in laboratory or clinical trials to reverse MDR are 
PGP inhibitors such as verapamil and cyclosporine A (Gottesman et al., 2002). 
Verapamil and cyclosporine A are competitive substrates for PGP-mediated 
drug transport. Through competing with anticancer drugs for transport by PGP 
protein, they can enhance the intracellular accumulation of anticancer drugs 
(Germann, 1996).  
 
In addition, the identification of substrates for the PGP efflux pump has also 
direct clinical benefits in cancer therapy, by which likelihood of sensitivity or 
resistance of cancer cells to the particular agent may be predicted. Therefore, 
PGP substrates identification is becoming a hot topic that continues to capture 
scientific attention. 
 
It has been known that clinical progress in brain tumor treatment is slow, and 
one of the important problems associated with these tumors is the weak 
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response to anticancer drugs. CNS is protected by BBB and CSF. The BBB 
has been reported to be an important place where PGP is over-expressed to 
prevent the penetration of cytotoxins (Demeule et al., 2001; Schinkel et al., 
1996). Brain tumors, such as neuroblastoma, meningiomas and some of 
glioma have also been reported to express high level of PGP 
(Spiegl-Kreinecker et al., 2002). Therefore, besides chemotherapy, non-viral 
vector-mediated gene therapy, as another promising therapy for brain tumors, 
may also encounter the efflux problem caused by PGP in the CNS.  
 
So far, no work has been done on the relationship between PGP pump and 
PEI-mediated gene delivery complexes in multidrug resistant tumor cells. To 
explore the possibility of further improving PEI-mediated gene delivery 
efficiency, it would be necessary to investigate whether PEI/DNA complexes 
could be PGP substrates in multidrug resistant tumor cells. Furthermore, it 
would also be worth to explore the effect of down-regulation of PGP on 
PEI-mediated gene delivery efficiency. Thus in this study, we investigated 
PEI-mediated gene delivery efficiency in tumor cells with different expression 
levels of PGP, and demonstrated that down-regulation of PGP expression 
could enhance PEI-mediated transgene expression.  
 
3.2 Materials and Methods 
3.2.1 Cell lines and culture  
Human breast cancer cell line MCF-7/ADR and its drug sensitive parental line 
MCF-7 were obtained from the National Cancer Institute, USA. Human glioma 
cell lines T98G and H4 and human hepatoma cell line HepG2 were purchased 
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from the American Tissue Type Culture Collection (ATCC, Manassas, VA, 
USA). Human cervical carcinoma derived drug sensitive KB-31 cell line and its 
multidrug resistant KB-31MA cell line were derived from the KB cell line 
(ATCC). All cells were cultured in Dulbecco's modified Eagle's medium (Gibco 
BRL) supplemented with 10% (v/v) fetal bovine serum, 100 units /ml penicillin, 
and 100 μg /ml streptomycin. All cultures were maintained in a humidified air 
/CO2 (19:1) atmosphere at 37°C. To maintain the multidrug resistance, 
MCF-7/ADR or KB-31MA cells were cultured in the medium containing 100nM 
of doxorubicin or 100 nM of vincristine respectively. 
 
3.2.2 Preparation of PEI/DNA complexes  
Plasmid DNA was diluted in 5% glucose. PEI (25kDa; Sigma-Aldrich, San 
Diego, CA, USA) was used as an aqueous stock solution containing 10 mM 
nitrogen. Ratios of PEI to DNA used for cell transfection were 5, 10 and 15 
equivalents of N/P, respectively. The required amount of PEI was calculated 
by taking into account that 1 μg of DNA contains 3 nmol of phosphate, and that 
1 μl of 10 mM PEI holds 10 nmol of amine nitrogen. PEI/DNA complexes were 
formed by adding the appropriate amount of PEI solution into the DNA solution, 
followed by mixing by vortexing and incubating for 30 min at room 
temperature.  
 
3.2.3 Gene delivery in vitro and luciferase activity assay  
Cells that were plated in 48-well plates at 2X104 cells / well one day before 
were transfected with PEI 25kDa/DNA complexes. Plasmids pGL3-CMV-Luc 
containing luciferase reporter gene under cytomegalovirus (CMV) promoter 
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constructed previously were used for transfection. Briefly, the culture medium 
was replaced with half the usual volume of serum-free OptiMEM (Invitrogen, 
Life Technologies, Inc., Carlsbad, CA), and 5 μl of PEI/DNA complexes 
containing 0.25 μg DNA was added to each well. After 4hr of incubation, the 
medium was changed back to usual growth medium. Luciferase activity was 
measured 24 hr later as described in chapter 2, section 2.2.5. 
 
3.2.4 Rhodamine efflux analysis 
Cells were aliquoted at 1X105 cells /ml and 1ml of cell suspensions were 
pre-warmed in a 37 °C incubator with 5% CO2 before the addition of 1 μg / ml 
Rhodamine 123 (Sigma-Aldrich, San Diego, CA, USA). After 30 minutes, cells 
were washed, resuspended in 50μl of OptiMEM, and appropriate PEI/DNA 
complexes or 50 μM verapamil were added into the suspension and were 
incubated for another 1 hr. Cells were then washed and suspended in 500 μl of 
PBS and the fluorescence were measured by fluorescence spectroscopy 
(Tecan, Switzerland) with excitation at 485 nm and emission at 535 nm. 
 
3.2.5 SiRNA preparation and transfection. 
The siRNA duplex sequence targeting MDR1 was designed according to the 
previous publication (Wu et al., 2003). The sense and antisense sequences 
used are: 5’-GGAAAAGAAACCAACUGUCdTdT (sense) and 
dTdTCCUUUUCUUUGGUUGACAG-5’ (antisense). Non-silencing siRNA was 
used as control: 5’-UUCUCCGAACGUGUCACGUdTdT (sense) and 
dTdTAAGAGGCUUGCACAGUGCA-5’ (antisense) (Qiagen, USA). 
MCF-7/ADR cells were plated on 6-well plates at 3X105 cells /well and 24 hrs 
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later cells were transfected with 4 μg of siRNAs targeting MDR1 or control 
siRNA per well using Lipofectamine 2000. After 24 hr and 48 hr, cells were 
collected for RT-PCR or Western blot analysis. 
 
3.2.6 Reverse Transcription –polymerase chain reaction (RT-PCR) 
Total RNA was extracted from MCF-7/ADR cells using RNeasy kit (Qiagen, 
USA). A total of 1 μg of RNA was reverse transcribed into cDNA using 
Omniscript RT Kit ( Qiagen, USA) with Oligo d[T]16 primer in a total volume of 
20 μl, containing 1X buffer RT, 2 mM dNTPs, 1 μM Oligo d[T]16 primer, 10 
units of RNase inhibitor, and 4 units of Omniscript Reverse Transcriptase. The 
RT reaction was performed for 1 hr at 37°C. After cDNA synthesis, 0.5 μl of RT 
product was taken and added to PCR SuperMix (Invitrogen Life Technologies, 
Inc., Carlsbad, CA) amplification reaction in 30 μl volume containing 0.5μM of 
MDR1 primers (5’-ATATCAGCAGCCCACATCAT-3’; 
5’-GAAGCACTGGGATGTCCGGT-3’) (Wu et al., 2003). GAPDH primers 
(5’-CCAAAAGGGTCATCATCTC-3’; 5’-GTAGAGGCAGGGATGATGTTC-3’) 
(Wu et al., 2003) were used as an internal control. Amplication cycles was 
performed at an initial denaturation at 95°C for 2 mins, followed by 23 cycles at 
95°C for 1 min，58°C for 1 min and 72°C for 1 min, with a final extension at 
72°C for 7 min. Aliquots of PCR product were electrophoresed on 1.5% 
agarose gels, and PCR fragments were visualized by ethidium bromide 
staining. 
 
3.2.7 Western Blotting 
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MCF-7/ADR cells were washed twice with PBS and then lysed in cold TNT 
buffer [20 mM Tris-HCL (pH 7.4), 200 mM Nacl, 1% Triton X-100, 1 mM 
phenylmethylsulphonyl fluoride, and 1% aprotinin]. The lysates were sonicated 
and then centrifuged at 12,000 rpm for 10 min at 4°C. Equal amount of protein 
(50 μg) were seperated by 7.5% SDS-PAGE and transferred to nitrocellulose 
membranes (Bio-Rad Laboratories, Hercules, CA). P-Glycoprotein was 
detected using monoclonal anti-P-glycoprotein antibody C219 (Calbiochem, 
San Diego, CA) at a dilution of 1:1000. GAPDH was detected by polyclonal 
anti-GAPDH antibody (Santa Cruz Biotechnology, Ic., Santa Cruz, CA) at 
1:2000. Secondary antibody was peroxidase-conjugated anti mouse IgG 
antibody (Sigma-Aldrich, San Diego, CA, USA) or goat anti-rabbit IgG antibody 
(Santa Cruz Biotechnology, Ic., Santa Cruz, CA). Signals were detected by 
supersignal chemiluminescence kit according to manufacturer’s instructions 
(Pierce, Rockford, IL).  
 
3.3 Results 
3.3.1 Effect of verapamil on PEI-mediated gene delivery efficiency in drug 
resistant tumor cell lines 
We first evaluated the effect of verapamil, a PGP inhibitor, on PEI-mediated 
gene transfer in HepG2, H4 and T98G tumor cell lines (Figure 3.1). We cells 
were transfected with PEI/DNA complexes, with addition of different amount of 
verapamil as indicated. HepG2 cells are PGP positive cells, and glioma cells 
(H4 and T98G) are known to be fairly resistant to anticancer drugs. Verapamil 
is a calcium antagonist and is generally used to inhibit PGP in multidrug 
resistant tumor cells. Results showed that the treatment with verapamil 
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increased PEI-mediated gene transfection efficiency in these three cell lines, 
although their responses to verapamil were different (Figure 3.1). In HepG2 
and T98G cells, 2 μM of verapmail treatment was enough to increase 
luciferase gene expression level, about 2 times higher compared to that 
without verapamil treatment. Gene expression reached a peak level at about 
10 μM of verapamil in HepG2 cells and about 20 μM of verapmail in T98G cells 
(Figure 3.1A and 3.1C). In H4, however, the highest expression level was 
observed at 2 μM of verapamil treatment, and then decreased with the 
increase of verapamil concentration (Figure 3.1B). These differences could be 
explained by their different multidrug resistance characteristics and different 
sensitivities to verapamil. At a relatively high concentration of verapamil (50 
μM), however, the expression level in all cell lines dropped, possibly due to the 
toxicity of verapamil (Figure 3.1). These results demonstrate that verapamil 
may sensitize these drug resistant tumor cells to the PEI-mediated gene 
delivery and subsequently enhance the transgene expression. This 
phenomenon is quite similar to that in chemotherapy where verapamil 
sensitize the multidrug resistant tumor cells to anticancer drugs, and thus it 
leads us to speculate that PEI-mediated gene delivery may be also influenced 
by the ATP-dependent efflux pump activities in multidrug resistant tumor cells. 
 
3.3.2 PEI-mediated gene delivery in PGP-positive and PGP-negative 
tumor cells  
Based on the above results, we began to examine the relationship between 
PGP and PEI-mediated gene delivery in drug resistant tumor cells. We 
investigated PEI mediated gene expression in two pairs of PGP-positive and 
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PGP-negative tumor cells. Figure 3.2 shows that PGP-positive MCF7/ADR 
cells had about 100 times lower luciferase expression level as compared to 
PGP-negative MCF7 cells at N/P ratio of 5 and 10, and about 1000 times lower 
at N/P ratio of 15. Furthermore, PEI-mediated gene expression level increased 
when MCF-7/ADR cells treated with verapamil as compared to that of cells 
without verapamil treatment; while there was no gene expression change after 
verapamil treatement in MCF-7 cells (Figure 3.3). Similar results were 
observed in PGP-positive KB-31MA cells and PGP-negative KB-31 cells, 
where without verapamil treatment KB-31MA cells had about 10 times lower 
PEI-mediated gene expression than KB-31 cells. However, with the addition of 
verapamil, KB-31MA cells had increased gene expression level, reaching 
almost the same as that of KB-31 cells, while gene expression in KB-31 cells 
did not change (Figure 3.4). The results imply that the activity of PGP may be 
the reason for the lower PEI-mediated gene expression in drug resistant 
MCF-7/ADR cells and KB-31MA cells than their corresponding drug sensitive 
parental cells. Inhibition of PGP by verapamil can increase the PEI-mediated 
gene delivery efficiency. Therefore we suspect that PEI/DNA complexes may 
serve as substrates of PGP and be transported out of cells by PGP after 
transfection. 
 
3.3.3 PEI/DNA complexes inhibit rhodamine123 efflux in PGP-positive 
tumor cells 
Rhodamine123 efflux assay was carried out to determine whether PEI/DNA 
complexes could be PGP substrates. Rhodamine123 has been used in 
imaging and in surrogate marker assays for PGP activity analysis in normal 
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and malignant human cells (Witherspoon et al., 1996). Here we treated 
MCF-7/ADR or KB-31MA cells with 1 μg/ml rhodamine123 for 30 min before 
further incubation with blank medium, PEI /DNA complexes or 25 μM of 
verapamil, respectively. Fluorescence intensity of rhodamine123 was 
measured to monitor the change of rhodamine123 accumulation in cells. 
Results showed that there was a high original rhodamine123 accumulation in 
cells after immediate treatment with rhodamine123, but with further incubation 
with blank medium for 1 hr, rhodamine123 accumulation reduced dramatically 
(Figure 3.5). This is because PGP on MCF-7/ADR or KB-31MA cell 
membranes pumps rhodmaine123 out of the cells during the incubation period, 
resulting in the reduction of rhodamine123 after its initial accumulation in cells. 
However, with further incubation with PEI/DNA complexes or verapamil for 1hr, 
the reduction of rhodamine123 in these cells was reversed to some extent, 
being about 3-fold higher than that incubated with blank medium (Figure 3.5). 
However, the level was still lower than the initial rhodamine123 accumulation 
(Figure 3.5). Verapamil is known as a competitive PGP substrate which can 
compete with rhodamine123 for transport by PGP, thus reversing the reduction 
of rhodamine123 accumulation caused by PGP. The similar results between 
PEI/DNA complexes treated cells and verapamil treated cells here suggest 
that PEI/DNA complexes may also serve as substrates of PGP. 
 
3.3.4 PEI-mediated gene delivery efficiency in PGP down-regulated tumor 
cells 
In order to study the specific effect of PGP on PEI-mediated gene transfer 
efficiency in multidrug resistant tumor cells, based on previous publication (Wu 
 62
Chapter 3. Down-regulation of P-Glycoprotein Increases Polyethylenimine-mediated 
Gene Expression 
et al., 2003), siRNA sequences targeting MDR1 gene that is known to encode 
PGP protein, namely siMDR1, were designed. We treated MCF-7/ADR cells 
with siMDR1 and analyzed its knock-down effect in MCF-7/ADR cells by 
RT-PCR and Western blotting. Control siRNA and blank medium were used as 
controls for the siRNA experiment procedure. As shown in Figure 3.6, siMDR1 
specifically reduced MDR1 mRNA levels dramatically after 24 hrs and 48 hrs 
compared with the control groups by RT-PCR. Western blot analysis also 
showed that siMDR1 reduced PGP protein level greatly after 24 hrs and the 
protein was almost undetectable after 48 hrs (Figure 3.7). These results 
confirmed the specific knock-down effect of siMDR1 on MDR1 mRNA and 
PGP protein level. Next, we down-regulated MDR1 gene in MCF-7/ADR cells 
using the small interfering RNA siMDR1 before transfection of PEI/DNA 
complexes. As shown in Figure 3.8, the pretreatment with siMDR1 significantly 
increased the PEI-mediated gene expression level when compared with 
control groups, reaching about 10-fold when 0.1 μg /well or 0.25 μg /well of 
siMDR1 was used. The result showed that specific down-regulation of PGP 
protein expression level increased PEI-mediated transgene expression level, 














Figure 3.1 Verapamil enhances PEI-mediated luciferase expression in HepG2 
(A), H4 (B) and T98G(C) cells. In 48-well plates HepG2, H4 or T98G cells were 
transfected with PEI/DNA complexes, with addition of various concentrations 
of verapamil as indicated, for 24 hours. The complexes were prepared with 
0.25 μg per well of pGL3-CMV-Luc plasmid and PEI 25 kDa at N/P ratio of 10. 
Luciferase activites are given in RLU /mg total protein+SD.* p<0.05 compared 
to the control group without verapamil treatment. ** p<0.01 compared to the 











Figure 3.2 Comparison of luciferase expression in MCF-7 and MCF-7/ADR 
cells. In 48-well plates MCF-7 or MCF-7/ADR cells were transfected with 
PEI/DNA complexes for 24 hrs. The complexes were prepared with 0.25 μg 
per well of pGL3-CMV-Luc plasmid and PEI 25kDa at different N/P ratios of 5, 











Figure 3.3 Effects of verapamil on PEI-mediated luciferase expression in 
MCF-7 and MCF-7/ADR cells. In 48-well plates MCF-7 or MCF-7/ADR cells 
were transfected with PEI/DNA complexes with addition of various 
concentrations of verapamil (10 μM, 25 μM, 50 μM) for 24 hours. The 
complexes were prepared with 0.25 μg per well of pGL3-CMV-Luc plasmid 
and PEI 25kDa at N/P of 10. The luciferase activities are presented as RLU 













Figure 3.4 Effects of verapamil on PEI-mediated luciferase expression in 
KB-31 and KB-31MA cells. In 48-well plates KB-31 or KB-31MA cells were 
transfected with PEI/DNA complexes with addition of 25 μM verapamil for 24 
hr. The complexes were prepared with 0.25 ug per well of pGL3-CMV-Luc 
plasmid and PEI 25kDa at N/P ratios of 10. The luciferase activities are 
presented as RLU /mg protein +SD.  
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Figure 3.5 Inhibition of rhodamine123 efflux from multidrug resistant cells by 
PEI/DNA complexes. In a 6-well plate, MCF-7/ADR or KB-31MA cells were 
treated with 1 ug/ml rhodamine123 for 30 min, washed, and incubated with 
plain OptiMEM medium (control), OptiMEM medium containing PEI/DNA 
complexes (1hr PEI/DNA) or OptiMEM containing 25 μM verapamil (1hr 
verapamil) for another 1 hr. Fluorescence intensity was measured by 
fluorescence spectroscopy. The fluorescence after immediate rhodamine123 
incubation was also measured as the original rhodamine123 accumulation 
level (0 hr) in cells. Plain OptiMEM medium was used as a blank control and 
OptiMEM medium containing verapamil was used as a positive control in 
which verapamil pumps the rhodamine123 out of cells during incubation. To 
form PEI/DNA complexes, 2 μg per well of PGL3-CMV-Luc plasmid was mixed 
with PEI 25 kDa at N/P ratio of 10.  * p<0.05 compared to the control group 











Figure 3.6 Effect of siRNA on MDR1 mRNA expression in MCF-7/ADR cells. In 
a 6-well plate, cells were transfected with 4 μg per well of siMDR1 or control 
siRNA or blank medium (normal). (siORF1 targeting MDR1 was not used for 
further experiments due to its insufficient knock-down effect,) 24 hr and 48 hr 
later, total RNA was extracted from the cells and reverse transcription reaction 
was performed. PCR amplication of cDNAs showed a 153bp fragment of 
MDR1 gene and a 286bp fragment of GAPDH. GAPDH gene was used as an 













Figure 3.7 Effect of siRNA targeting MDR1 on PGP protein expression in 
MCF-7/ADR cells. In a 6-well plate, cells were transfected with 4 μg per well of 
siMDR1 or control siRNA using Lipofectamine 2000, or without any siRNA 
(normal). 24 hr and 48 hr later, cell lysates were collected and separated by 
7.5% SDS-PAGE, then transferred onto nitrocellulose membrane. Detection of 
PGP protein was performed using enzyme-linked chemiluminescence. 












Figure 3.8 Effect of siRNA targeting MDR1 on the PEI-mediated luciferase 
expression in MDR-7/ADR cells. In a 48-well plate MCF-7/ADR cells were 
transfected with various amount of siMDR1 (0.1 μg/well and 0.25 μg/well) or 
control siRNA or blank medium using Lipofectamine 2000. After 48 hours cells 
were washed and further transfected with PEI/DNA complexes. The 
complexes were prepared with 0.25 μg per well of pGL3-CMV-Luc plasmid 
and PEI 25kDa at N/P ratio of 10. Luciferase activities were measured 24 hrs 
later and are presented as RLU/mg protein+SD. * p<0.05 compared to the 
control siRNA group. 
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3.4 Discussion  
Cationic polymers such as PEI have been widely tested as gene delivery 
vectors because they raise none of the concerns of viral vectors for human 
gene therapy. For cancer gene therapy, PEI also has shown some promise in 
delivering reporter gene or therapeutic gene into tumor cells such as brain 
tumors. However, as cancer cells such as brain tumor cells demonstrate MDR, 
mainly caused by PGP efflux pump which confers a key obstacle for cancer 
chemotherapy, and CNS structures such as BBB also display a high level of 
PGP expression to prevent access of exnobiotics, it would be reasonable to 
speculate that PEI-mediated gene delivery into brain tumors in a form of 
macromolecules, may also be affected by PGP efflux pump.  
 
Therefore, in order to investigate the possibility of further improving 
PEI-mediated gene delivery efficiency, we explored the relationship between 
PEI/DNA complexes and PGP efflux pump in multidrug resistant tumor cells. 
This would be very useful if non-viral gene therapy is to be applied to multidrug 
resistant tumors such as brain tumors.  
 
PEI-meidated gene delivery efficiency affected by MDR 
We have reported that PEI-mediated gene transfer efficiency was lower in 
PGP-positive tumor cells than in PGP-negative tumor cells, and that inhibition 
of PGP efflux pump with verapamil in PGP-positive cells increased 
PEI-mediated gene delivery efficiency. Verapamil, as a PGP substrate as well 
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as a PGP inhibitor, can inhibit PGP function. The verapamil treatment in these 
results seemed to sensitize the cells to PEI-mediated gene delivery complexes, 
which is similar to the situation in chemotherapy where verapamil can sensitize 
the cells to cytotoxic drugs. This indicates that PEI-mediated gene delivery 
efficiency was impaired in PGP-positive cells possibly due to the PGP efflux 
activity. 
 
Rhodamine123 has been widely used in PGP functional assays as it is a 
selective PGP substrate (Bucana et al., 1990; Feller et al., 1995; Ludescher et 
al., 1991; Weaver et al., 1991), and it has been used to identify possible PGP 
modulators by monitoring the PGP activity before and after administration of 
candidate agents. Our rhodamine123 efflux assay showed that PEI/DNA 
complexes, like verapamil, reduced rhodamine123 efflux caused by PGP 
pump in multidrug resistant tumor cells. The similar effect between PEI/DNA 
complexes and verapamil implies that PEI/DNA complexes could also be a 
PGP modulator, functioning in a way that is similar as verapamil. Complexes 
could compete with rhodamine123 for transport by PGP, thus reversing the 
reduction of rhodamine123. 
 
We further demonstrated that the specific down-regulation of MDR1 mRNA as 
well as PGP protein level by specific siRNA targeting MDR1 gene significantly 
enhanced PEI-mediated transgene expression level in drug resistant cells. 
This indicates the specific involvement of PGP in regulating PEI-mediated 
gene delivery.  
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The association between PGP and PEI/DNA complexes indicates a new 
approach to improve PEI-mediated gene delivery efficiency in multidrug 
resistant tumor cells by inhibiting or down-regulating PGP with pharmaceutical 
molecules or biological molecules, which further brightens the future of 
PEI-mediated gene therapy for cancers such as brain tumors. 
 
Novel PGP inhibitors with low toxicity and greater specificity are needed 
In human cancer therapy, identification of PGP substrates has direct clinical 
benefits because MDR remains to be a significant obstacle to providing 
effective chemotherapy. Many strategies have been developed to overcome 
and eventually prevent MDR in clinic. Although a number of different 
mechanisms can lead to the development of MDR, the classic resistance to 
cytotoxic drugs is caused by PGP overexpression (Gottesman et al., 2002). 
Therefore inhibiting PGP as a way of reversing MDR has been extensively 
studied for more than two decades. Since 1980s, many PGP inhibitors have 
been identified from the first to current third generation (Seelig, 1998; Thomas 
and Coley, 2003). The clinical efficacy of the first and second generations of 
PGP inhibitors which are PGP substrates has proven to be fairly disappointing, 
primarily due to their high toxicity. Moreover, these PGP inhibitors also function 
as substrates for other transporters, particularly those of ABC transporter 
family, inhibition of which could lessen the ability of normal cells and tissues to 
protect themselves from cytotoxic agents (Krishna and Mayer, 2000; Wandel 
et al., 1999). The third-generation PGP inhibitors that are developed recently 
show greater specificity and lower toxicity profiles than their predecessors. 
Tariquidar, for example, binds specifically and noncompetitively with high 
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affinity to the PGP transporters and potently inhibits their activities. However, 
further clinical trials need to be done to demonstrate safety and efficacy of the 
third generation of PGP inhibitors. 
 
Combination of PEI-mediated gene therapy, PGP inhibitors, and/or 
chemotherapy are needed in drug resistant tumor cells 
The responses of multidrug resistant cells to PEI/DNA complexes shown in 
this study are quite similar to their responses to cytotoxic chemotherapeutic 
drugs. This suggests that PEI/DNA complexes, like cytotoxic drugs, could also 
be PGP substrates. Thus PGP could also form an obstacle for PEI-mediated 
cancer gene therapy. In this light, like chemotherapy, efficient and specific 
PGP inhibitors should be applied with PEI-mediated gene therapy to overcome 
and eventually prevent PGP functional activity in order to enhance gene 
delivery efficiency. Combination of PEI-mediated gene therapy with 
chemotherapy and PGP inhibitor treatment for cancer therapy may both 
improve the efficiency of gene therapy and chemotherapy, achieving better 
treatment effect.  
 
On the other hand, with the ability of condensing nuclei acids, PEI could also 
be used to deliver agents that specifically inhibit MDR1 gene, and thus 
sensitize tumor cells to chemotherapy. In fact, several recent reports have 
indicated the successful delivery of small interfering RNA or double strand 




Chapter 3. Down-regulation of P-Glycoprotein Increases Polyethylenimine-mediated 
Gene Expression 
Other ABC transporters to be considered in brain tumors 
It has been reported that besides PGP, some other ABC transporters such as 
MRP1 are also abundantly expressed in CNS structures such as choroid 
plexus where they serve to pump the metabolic waste products of CSF into the 
blood (Rao et al., 1999). MRP1 was also over-expressed in most glioma cells 
(Spiegl-Kreinecker et al., 2002). Thus investigating the role of MRP1 in 
PEI-mediated gene delivery efficiency also has beneficial impact on cancer 
gene therapy. In this study, we did not investigate the relationship between 
PEI-mediated gene delivery complexes and MRP1. However, the same 
strategy in this study could be used to determine the association of MRP1 and 
PEI-mediated gene delivery complexes.  
 
To our knowledge, this is the first report demonstrating the relationship 
between PGP efflux pump and PEI-mediated gene delivery system in 
multidrug resistant tumors. However, it remains unclear which component, PEI 
or DNA, plays the main role in the interaction with PGP. Although more 
detailed mechanisms of the PGP and PEI interactions has to be elucidated for 
a better understanding, our results nevertheless highlights the importance to 
consider the multidrug resistance status of target tumor cells when using 
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Chapter 4. A Histone Deacetylase Inhibitor Improves Baculovirus-mediated Gene  
Therapy in Glioma 
4.1 Introduction 
Gliomas, which occur in the glial, or supportive tissues around the brain, are 
the most prevalent primary tumors in the central nervous system. One type of 
gliomas, GBM, is also known to be the most aggressive and malignant Grade 
IV astrocytoma. GBM accounts for about 30% of all primary brain tumors and 
mainly happens in middle-aged adults. The prognosis of glioma remains 
extremely poor and has not changed over the last two decades, despite 
advances in conventional therapies (i.e., surgery, radiotherapy, and 
chemotherapy). The average life expectancy in patients is usually less than 1 
year (Komata et al., 2001). As such, novel therapeutic strategies such as gene 
therapy should be considered and explored for glioma treatments. Given the 
complexity of the brain structure, more efforts are being made to develop and 
explore new vectors tailored for gene delivery into the brain. 
 
In the past years, non-viral and viral vectors have been investigated for gene 
delivery to glioma cells. Zerrouqi et al. reported that liposomal delivery of 
reporter genes into glioma cells could be achieved, with the transfection 
efficiency reaching 36% in vitro and 18.6% in vivo after an intra-tumoral 
injection of liposome/DNA complexes (Zerrouqi et al., 1996). Yoshida et al. 
also studied transfer of anti-cancer molecules using liposomes and found 
regression of experimental gliomas, resulting in the establishment of some 
original and effective therapies (Yoshida and Mizuno, 2003). However, with 
these achievements, non-viral vectors still cannot challenge viral vectors in 
cancer gene therapy due to their relatively lower transgene expression level 
compared to viral vectors. Adenoviral and retroviral vectors have been the 
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most commonly used tools for the delivery of therapeutic genes into malignant 
gliomas and have been applied in early phase clinical trials. 
Replication-deficient retrovirus carrying HSV-tk gene was reported to treat 
patients with glioblastoma; however, the transduction efficiency was found to 
be very low (Harsh et al., 2000; Puumalainen et al., 1998). One phase III trial 
showed that standard therapy (surgical resection and radiotherapy) or 
standard therapy plus adjuvant retrovirus-mediated HSV-tk gene therapy 
during surgery in human glioblatoma exhibited no difference in survival or in 
safety (Rainov, 2000). On the other hand, adenovirus-mediated HSV-tk gene 
therapy in some early clinical trials showed some positive responses in human 
glioblastomas. Sandmair et al. reported a significantly longer mean survival 
time in adenovirus-mediated HSV-tk gene therapy group (15 months) than in 
retrovirus-mediated HSV-tk gene therapy group (7.4 months) and 
adenovirus-mediated reporter gene therapy group (8.3 months) (Sandmair et 
al., 2000). However there were some cases of adverse effects such as 
short-term fever, seizures and transiently increased intracranial pressure 
(Immonen et al., 2004; Sandmair et al., 2000; Trask et al., 2000). 
 
Recently, baculovirus vectors, especially the most well-studied and used 
AcMNPV, has attracted much attention as a novel viral vector with many 
advantages over the other viral vectors. As they are non-mammalian insect 
viruses, baculoviruses are unable to replicate and express viral proteins in 
mammalian cells, thus significantly reducing the chance of provoking antiviral 
humoral and cellular immunity in mammals. More importantly, with broad 
tropism for both proliferating and non-proliferating cells, baculovirus can 
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provide high transduction efficiency in many different types of cells and tissues, 
including some tumor cell lines (Kost and Condreay, 2002; Kost et al., 2005). 
The large cloning capacity conferred by the large viral genome of baculovirus 
has also made baculovirus a popular vector to deliver large functional gene(s). 
Moreover, the easy production and manipulation of baculovirus vector make 
the large-scale preparation of high titer vectors simple and thus make it 
feasible for future pharmaceutical application. Because of the above 
mentioned advantages, baculovirus is becoming a very useful tool for gene 
delivery. 
 
However, it has been shown that baculovirus was easily inactivated after 
exposure to serum complements when used as a gene vector for systemic 
delivery; this greatly limited gene transfer by baculovirus into most organs, like 
liver in vivo (Hofmann and Strauss, 1998). The CNS, protected by the BBB, is 
virtually isolated from circulating immunological factors including complement 
components (Carson and Sutcliffe, 1999), thus serving as a suitable organ for 
baculovirus-mediated gene delivery. Previous reports showed that direct 
injection of baculovirus vectors to the brain caused a minimum damage and 
hemorrhage, and gave satisfactory levels of transgene expression (Li et al., 
2004; Li et al., 2005; Sarkis et al., 2000). Recently, our group also reported 
that baculovirus displays a high tropism for astrocytes, with about 70% of the 
viruses injected into the striatum found in astrocytes (Li et al., 2004). These 
results suggest that baculovirus may be a good candidate vector in gene 
delivery for the treatment of astrocytomas such as GBM. The transient nature 
of gene expression mediated by baculovirus has limited their application in 
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gene therapy because neurodegenerative disorders such as amyotrophic 
lateral sclerosis require sustained therapeutic gene expression in the CNS. 
Previous studies have shown that peak levels of in vitro and in vivo gene 
expression driven by the CMV promoter placed into baculovirus vectors lasted 
for just several days and dropped quickly afterwards (Condreay et al., 1999; 
Lehtolainen et al., 2002). However, for brain tumor gene therapy, a high 
transgene expression level rather than a long-lasting intermediate expression 
is required to kill tumor cell efficiently. Thus baculovirus still serves as a 
suitable gene delivery vector for brain tumors such as GBM.  
 
It has been shown that the transduction efficiency of baculovirus vector can be 
markedly enhanced by the addition of HDAC inhibitors such as sodium 
butyrate or trichostatin A (Condreay et al., 1999). HDAC inhibitors interact with 
the catalytic site of HDACs and thus induce a hyperacetylation of the 
chromatin and enhancement of transcription (Finnin et al., 1999). Recently 
HDAC inhibitors have also been shown to be novel anti-tumor reagents as 
almost all HDAC inhibitors can induce cell cycle arrest, differentiation, or 
apoptosis in vitro and many have anti-tumor effects in vivo as well (Johnstone, 
2002; Weidle and Grossmann, 2000; Yoshida et al., 2001). Sodium butyrate 
(NaB), a short fatty acid, is a histone deacetylase inhibitor and is produced in 
the colonic lumen as a consequence of microbial degradation of dietary fibers. 
Sodium butyrate has been reported to significantly inhibit proliferation and 
invasiveness of both U251MG and U87MG glioma cells in a dose-dependent 
manner. It also increased p21 expression level independent of the p53 status 
(Ito et al., 2001). Intratumoral infusion of sodium butyrate has also been shown 
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to prolong survival of a C6 glioma transplanted rat model (Engelhard et al., 
2001). 
 
Mutation or inactivation of p53, a tumor suppressor gene, is one of the early 
genetic alterations that may confer a proliferative advantage to glial cells and is 
associated with the progression of glioma (Sidransky et al., 1992) . Because 
there are about half of gliomas containing mutant p53, therapies aimed at 
restoring wild type p53 function or specifically targeted at killing cells with 
mutant p53 might be of benefit (Bischoff et al., 1996; Wieczorek et al., 1996). 
Adnovirus-mediated p53 gene transfer was reported to inhibit the growth of 
implanted gliomas and prolong the survival in preclinical models 
(Gomez-Manzano et al., 1996; Lang et al., 1999). Lang et al. demonstrated 
that adenovirus-mediated p53 gene transfer into gliomas with mutant p53 
resulted in massive apoptosis in vitro and inhibited tumor growth in vivo (Lang 
et al., 1999). In contrast, glioma cells with wild type p53 are resistant to the 
apoptotic effects of p53 transfer (Lang et al., 1999).  
 
Combination therapy is usually necessary for successful cancer treatment, 
especially in cancers like maglinant glioma where tumor cells are resistant to 
one or even several conventional therapies. In this study, in an effort to 
achieve optimal anti-tumor effects, we developed a novel strategy to combine 
baculovirus-mediated tumor suppressor gene p53 delivery with a HDAC 
inhibitor, sodium butyrate, to treat U251 gliomas that contained a mutant p53. 
As for p53 status, U251 cells have a mutant type p53 (mtp53) gene (Kondo et 
al., 1996; Van Meir et al., 1994). A synergistic anti-tumor effect of the 
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combination treatment was observed in U251 glioma cells in comparison to 
baculovirus-mediated wild type p53 (wtp53) therapy alone or sodium butyrate 
treatment alone. Hence, we provide evidence showing that HDAC inhibitors 
together with baculovirus-mediated wtp53 gene therapy are very effective in 
treating mutant p53 gliomas.  
 
4.2 Materials and Methods 
4.2.1 Cell lines and culture  
Human malignant glioma U251 cells were purchased from JCRB (Japanese 
Collection of Research Bioresources, Japan). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, GIBCO BRL, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS, GIBCO BRL, USA), 
100 IU /ml penicillin and 100 μg /ml streptomycin in a humidified incubator with 
5% CO2 at 37°C. 
 
4.2.2 Baculovirus vectors 
Recombinant baculovirus vectors were constructed according to the manual of 
Bac-To-Bac Baculovirus Expression system (Gibco BRL, USA). Briefly, CMV 
immediate-early promoter was amplified from pRC/CMV2 (Invitrogen, 
Carlsbad, CA) and subcloned into the transfer plasmid pFastBac1 (Invitrogen, 
Carlsbad, CA) at NotI and XhoI sites. Human wild type p53 cDNA amplified by 
PCR from pORF-hp53 vector (InvivoGen, San Diego, CA, USA) and the 
enhanced green fluorescent protein (EGFP) reporter gene amplified from 
pEGFP-C1 vector (BD Clontech, USA) were subcloned into pFastBac1 
downstream of CMV promoter at XhoI and HindIII sites respectively. The 
 83
Chapter 4. A Histone Deacetylase Inhibitor Improves Baculovirus-mediated Gene  
Therapy in Glioma 
oligonucleotides used in PCR were as follows: human wtp53 (forward primer: 
5'-TCCTCCCTCGAGATGGAGGAGCCGCAGTCAGAT-3'; reverse primer: 
5'-GCGTTCAAGCTTTCAGTCTGAGTCAGGCCCTT-3') and EGFP (forward 
primer: 5'-CATAACTCGAGCGCCACCATGGTGAGCAA-3’; reverse primer: 
5'-TCTGAGAAGCTTCTTGTACAGCTCGTCCATGCC-3’). Another pFastBac1 
vector carrying a firefly luciferase reporter gene under the control of CMV 
promoter constructed by Dr. Li Y. was also used in this study. These viral 
vectors were produced and propagated in Sf9 cells according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA) and were named as 
BV-CMV-P53, BV-CMV-EGFP and BV-CMV-Luci (Figure 4.1). Viral vectors 
were concentrated from cell culture medium by centrifugation at 28,000 g for 1 
hr at 4°C and the pellets were resuspended in appropriate volume of PBS. 
Titers (plaque-forming units, PFU) of the recombinant baculovirus vector 
stocks were determined by plaque assay on Sf9 cells.  Figure 4.1 shows the 
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Figure 4.1 Schematics of the expression cassettes of the recombinant 
baculovirus vectors used in this study. Abbreviations: BV, baculovirus vector; 
CMV, the CMV immediate-early gene promoter; Luci, luciferase gene; EGFP, 
enhanced green fluorescence protein gene; wtp53, wild type p53 gene. 
 
 
4.2.3 Baculovirus transduction 
To test baculovirus vectors in vitro, U251 cells were seeded in cell culture 
plates at 30% confluency 24hr before experiments.  After removing cell 
culture medium, appropriate serum-free OptiMEM containing baculovirus at a 
different multiplicity of infection (MOI) with or without desired amount of sodium 
butyrate was added into each well and incubated at 37°C for 1-2 hr. The 
medium was then replaced by complete growth medium with or without 
appropriate amount of sodium butyrate (Sigma-Aldrich, USA). Cells were 
further incubated at 37°C for appropriate time before subsequent experiments 
were carried out. 
 
4.2.4 Luciferase activity assay  
luciferase activity assay was carried out as described in Chapter 2, section 
2.2.5. 
 
4.2.5 Western blotting 
Transfected U251 cells were harvested and homogenized by sonication in 
ice-cold 1% Triton X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM 
Tris-HCl [pH 8.0], 0.1% sodium dodecyl sulfate [SDS], 5 mM EDTA, and 
protease inhibitors). After centrifugation, the protein concentration of the 
supernatant was determined. 50 μg of total protein were resolved by 12% 
SDS–PAGE and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad, 
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Hercules, CA). The membranes were incubated in a mouse monoclonal 
anti-p53 primary antibody (BD Clontech, USA) or a rabbit polyclonal 
anti-acetylated histone H4 primary antibody (Upstate, NY) at 1:1000 dilution, 
followed by a horseradish peroxidase (HRP)-conjugated goat anti-mouse 
secondary antibody (Sigma-Aldrich, USA), or HRP-conjugated goat anti-rabbit 
secondary antibody (Sigma-Aldrich, USA) at 1:2000 dilution. The membranes 
were visualized with a supersignal chemiluminescence kit (Pierce, Rockford, 
IL). After incubation in restore Western blot stripping buffer (Pierce 
Biotechnology, Rockford, IL), the membranes were reprobed with a rabbit 
polyclonal anti-GAPDH primary antibody (Santa Cruz Biotechnology) diluted 
1:1000 for an internal control. 
 
4.2.6 Immunohistochemistry 
Cells incubated in a 24-well plate were washed twice with 0.1M PBS (pH7.4) 
and fixed with 4% paraformaldehyde in 0.1 M PBS (pH 7.4) for one hour at 
room temperature (RT). After washing in 0.1 M PBS for three times, cells were 
incubated in 3% H2O2 /methanol solution for 10 min at RT and then in 0.2% 
Triton X-100 /0.1 M PBS for 20 min. After three rinses in 0.1 M PBS, the cells 
were blocked with 2% goat serum in 0.2% Triton X-100 /0.1 M PBS for 1 hr. 
Mouse anti-p53 and cy3-conjugated anti-mouse polyclonal antibody 
(Sigma-Aldrich, USA) were used as the primary and secondary antibodies 
respectively. Cells were counterstained with 1 μg/ml Hoechst stain 
(Immunohistochemistry Technologies, USA). Immunofluoresence was directly 
detected under microscope and photographs were taken with digital camera 
attached to the microscope (Olympus IX 71, Japan). 
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4.2.7 MTT cytotoxicity assay 
Cells were seeded in a 96-well microtiter plate at density of 1x104 cells per well 
with 150 μl of cell culture medium. After 24 hr, cells were transfected with 
recombinant baculovirus vectors at different MOI with or without appropriate 
amount of sodium butyrate. After incubation, MTT assay was done as describe 
previously in Chapter 2, section 2.2.4. 
 
4.2.8 TUNEL staining 
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate 
(dUTP) nick end labeling (TUNEL) assay was performed using an In Situ Cell 
Death Detection Kit (Roche, USA) suggested by the manufacturer. Briefly, 
cells were prepared the same as those for immunostaining assay. After 1hr of 
fixation at room temperature, cells were rinsed with PBS and incubated in 3% 
H2O2 /methanol solution for 10 min at RT and then were incubated in a 
permeabilisation solution containing 0.1%Triton X-100 in 0.1% sodium citrate 
for 2 min at 4°C. After rinsing twice with PBS, 50 µl of TUNEL reaction solution 
was added to each sample. After 60 min incubation at 37°C and washing, 
samples were analyzed under a fluorescence microscope (Olympus IX 71, 
Japan). For the negative control, samples were incubated in 50 µl of a label 
solution without terminal transferase. 
 
4.2.9 Flow cytometry 
Cells were seeded and infected with appropriate amount of baculovirus 
vectors with or without sodium butyrate in 6-well plates. After 24 hr cells were 
collected and phosphatidylserine positive cells were detected by an Annexin-V 
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FITC Apoptosis Detection kit (Calbiochem, Darmstadt, Germany) according to 
the manufacturer’s protocol. Briefly, treated cells were collected, washed, and 
suspended in 1X binding buffer at 1X 106 cells /ml. 0.5 ml of cell suspension 
was transferred to a microfuge tube and 10 μl media binding reagent was 
added into the cells, followed by 1.25 μl Annexin V-FITC. After incubation at 
room temperature for 15 min in the dark, cells were centrifuged and 
resuspended in 0.5 ml cold 1X binding buffer. 10 μl propidium iodide (PI) was 
added and the samples were kept on ice away from light. Cells unstained, 
stained with Annexin-V FITC alone, or stained with PI alone were used as 
negative controls. Cells were analyzed by flow cytometry on a BD FACScan 
using CellQuest software (Becton Dickinson, San Jose, CA). 
 
For DNA content analysis, cells were harvested, washed and suspended in 
buffer (PBS / 2% FBS) at 1-2X106 cells /ml. After aliquoting 1 ml cells in a 15 
ml polypropylene tube, 3 ml cold absolute ethanol was added dropwise while 
vortexing into the cells. Cells were kept in fixative at 4°C for at least 2 hr. Cells 
were washed twice in PBS and labeled by 50 μg /ml propidium iodide (PI) 
(Sigma-Aldirch, USA) staining solution containing 200 μg /ml DNase-free 
RNase A (Sigma-Aldirch, USA) for 30 min before analyzed by flow cytometry 
on a BD FACScan using CellQuest software (Becton Dickinson, San Jose, 
CA).  
 
4.2.10 In vivo study 
Female BALB/c homozygous nude (nu/nu) mice of about 8 weeks of age were 
maintained in a pathogen-free environment throughout the experiment. Human 
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GBM-derived cell line U251 (3x106 cells) in 0.1 ml PBS were injected 
subcutaneously into the left and right flanks of nude mice using a 27-gauge 
needle. When tumor sizes reached 5-8 mm diameter (day 10 after tumor 
implantation), animals were treated consecutively for 6 days with intratumoral 
injections of 50 μl 1XPBS, 5 mM NaB alone, 5 X108 BV-CMV-p53 alone, 5X108 
BV-CMV-Luci alone, 5 mM NaB combined with 5X108 BV-CMV-p53, or 5 mM 
NaB combined with 5X108 BV-CMV-Luci. Tumor size was monitored every 
other day from day 10 onwards and the tumor size at day 10 was taken as the 
starting reference size. The length and width of the tumors were measured 
with a caliper. Tumor volume was calculated as (width2) X (length) /2 and 
tumor growth speed was calculated by the ratio of the tumor size at indicated 




4.3.1 Sodium butyrate Improved baculovirus-mediated transgene 
expression in cultured cells 
To generate baculovirus vectors to be used for this study, CMV 
immediate-early promoter was subcloned into the transfer plasmid pFastBac1 
(Invitrogen, Carlsbad, CA) at NotI and XhoI sites. Human wild type p53 (wtp53) 
cDNA or the enhanced green fluorescent protein (EGFP) reporter gene were 
then subcloned downstream of CMV promoter. Another pFastBac1 vector 
carrying a firefly luciferase reporter gene under the control of CMV promoter 
constructed by Dr. Li Y. was also used in this study. Thus three viral vectors 
were produced and propagated in Sf9 cells and were named as BV-CMV-P53, 
BV-CMV-EGFP and BV-CMV-Luci respectively (Figure 4.1).  
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To examine the effect of sodium butyrate on baculovirus-mediated reporter 
gene expression in U251 glioma cells, cells were infected with BV-CMV-Luci at 
MOI of 50 with the addition of increasing amounts of NaB from 1 mM to 20 mM 
for one, two or three days. As shown in Figure 4.2, addition of NaB to infected 
cells increased luciferase activity 10- to 200- fold in U251 cells after one day in 
comparison to infection without NaB. After two or three days, low dosage of 
NaB (1 mM-2 mM) did not increase the luciferase activity at all, while relative 
higher dosage of NaB (5 mM-20 mM) could still enhance the luciferase activity 
although the magnitude of increase was reduced (Figure 4.2). This result 
showed that NaB could improve baculovirus-mediated luciferase expression 
level in a dose- and time- dependent manner.   
 
Although the enzymatic activity of luciferase is a sensitive quantitative method 
to evaluate gene transfer efficiency, the number of EGFP-positive cells would 
be more indicative of the percentage of transduced cells. We thus treated cells 
with BV-CMV-EGFP and NaB to examine the percentage of glioma cells 
expressing EGFP. Flow cytometry and fluorescence microscopy both showed 
that baculovirus-mediated EGFP expression was greatly increased in U251 
cells after addition of NaB at a concentration as low as 2 mM (Figure 4.3 &4.4). 
Cells infected with BV-CMV-EGFP at MOI of 50 only exhibited about 30% 
EGFP-positive cells after 24hr, while with the addition of 2 mM of NaB 80% 
EGFP-positive cells could be achieved (Figure 4.3) . Further increase of NaB 
concentration (5 mM-20 mM) could achieve more than 90% EGFP-positive 
cells (Figure 4.3). The green fluorescence signal under microscopy was also 
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dramatically enhanced in cells infected with a combination of BV-CMV-EGFP 
at MOI of 25 and NaB (2 mM-20 mM) when compared to that of cells infected 
without NaB (Figure 4.4). These results further confirmed previous publications 
in which NaB was used to enhance baculovirus-mediated protein expression 
level (Condreay et al., 1999).  
 
Since NaB was found to increase baculovirus-mediated reporter gene 
expression (Figures 4.2-4.4), we then went on to determine the effect of NaB 
on baculovirus-mediated p53 expression in glioma cells by immunoblotting and 
immunohistochemistry.  
 
To confirm the transduction of BV-CMV-p53 in U251 cells, immunoblotting was 
performed to detect p53 after baculovirus infection. Cells were infected with 
BV-CMV-p53 alone at increasing MOI from 10 to 200 for 24 hr. At MOI below 
100, BV-CMV-p53 infected cells did not show p53 over-expression compared 
with uninfected cells. At relative higher MOI of 100 and 200, cells exhibited 
slightly higher p53 protein level than cells without infection (Figure 4.5). In the 
control group where cells infected with BV-CMV-Luci at increasing MOI, p53 
protein level did not change (Figure 4.5). To examine the effect of NaB on 
BV-CMV-p53 transduced cells, we treated cells with NaB alone, BV-CMV-Luci 
(MOI 100) combined with NaB, or BV-CMV-p53 (MOI 100) combined with NaB, 
respectively, for 24 hr. Figure 4.5 shows that when U251 cells were treated 
with NaB alone or BV-CMV-Luci combined with NaB, the endogenous p53 
protein expression level diminished with increasing NaB dosage from 0 mM to 
20 mM. This may be due to the increasing cell death caused by NaB. However, 
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when U251 cells were infected with BV-CMV-p53 in the presence of NaB, p53 
protein level increased with increasing NaB dose (Figure 4.6). Considering the 
decreased p53 level in other two control groups, p53 protein over-expression 
in cells infected by BV-CMV-p53 combined with NaB was quite significant. This 
significance is mainly attributed to the presence of NaB, because as shown in 
Figure 4.5, in the absence of NaB only slight p53 over-expression could be 
achieved. Western blot for acetylated histone H4 protein was also carried out 
to confirm the function of NaB. Results of all three groups showed there was 
little acetylated histone H4 protein detected in cells without NaB treatment. 
However, acetylated H4 protein level was dramatically increased with increase 
dosage of NaB (Figure 4.6), which confirmed the hyperacetylation function of 
NaB as a HDAC inhibitor.  
 
Similar results were demonstrated using immunohistochemistry. We treated 
cells with BV-CMV-p53 or BV-CMV-Luci at MOI of 100, with or without NaB 
(5mM). Cells without treatment or with NaB (5 mM) treatment alone were also 
used for controls. As shown in Figure 4.7, p53 fluorescence was almost 
undetectable in all control cells. Some positive p53 staining was observed in 
BV-CMV-p53 (MOI 100) infected cells. NaB greatly enhanced p53 expression, 
which was evident by an obviously increased percentage of p53 positive cells 
and a higher intensity of p53 staining upon the addition of 5 mM NaB (Figure 
4.7).  
 
These results show that p53 protein can be slightly over-expressed by 
BV-CMV-p53 infection alone at MOI higher than 100, however, NaB can 
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further dramatically enhance baculovirus-mediated p53 over-expression at 
concentration as low as 5 mM (Figure 4.5 -4.7). 
 
4.3.2 Cytotoxicity of baculovirus-mediated p53 and /or sodium butyrate 
in vitro 
After showing that p53 protein could be effectively over-expressed in 
BV-CMV-p53 infected cells in the presence of NaB (Figure 4.5 -4.7), we then 
examined the anti-tumor effects of NaB and /or BV-CMV-p53 in p53-defective 
glioma cells. We treated U251 cells with different amounts of NaB or 
BV-CMV-p53 or both and evaluated their effect on cell survival by MTT 
assays.  
 
Figure 4.8 shows that NaB alone induced cell death in U251 cells with both 
dose- and time-dependent responses. In the first 48 hr after NaB treatment, 
cells almost did not exhibit any cell death. However, after 72 hr as indicated by 
a decrease in cell viability, obvious cell death was observed, which is directly 
corresponding to the NaB concentration. Five micromolar NaB induced about 
20% cell death after three days while 20 mM NaB induced around 30%-40% 
cell death (Figure 4.7). This result demonstrated that NaB (1 mM to 20 mM) 
alone could induce cell death, but might need some time before killing tumor 
cells.  
 
To demonstrate the cytotoxic effect of BV-CMV-p53 on glioma cells, we 
infected BV-CMV-p53 or BV-CMV-Luci in U251 cells at different MOI (10-200). 
Within the first 24 hr, cells in both groups did not show much difference on cell 
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viability. After 48-72 hr, cells infected by BV-CMV-p53 at MOI of 200 exhibited 
only about 25% cell death as compared to 10% in control cells infected with 
BV-CMV-Luci (Figure 4.9), which indicated that BV-CMV-p53 treatment alone 
at MOI from 10 to 200 was not very efficient in killing glioma cells. Although 
slight increase of cell death was observed with increasing BV-CMV-p53 MOI 
from 10 to 200, the dose-dependent cytotoxicity effect was not so dramatic 
(Figure 4.9). This is consistent with the Western blot result where only slight 
p53 over-expression could be achieved with the MOI we used, thus the wtp53 
may not be enough to induce tumor cell death.  
 
To examine the cytotoxic effects induced by combination of BV-CMV-p53 and 
NaB, we treated cells with BV-CMV-p53 at MOI 50 with increasing dose of 
NaB from 1 mM to 20 mM. Within the first 24 hr when NaB (20 mM) did not 
induce cell death while BV-CMV-p53 (MOI 50) induced less than 10% cell 
death, the combination of NaB (20 mM) and BV-CMV-p53 (MOI 50) induced 
about 25% cell death (Figure 4.10). After three days, 20 mM NaB alone 
induced about 40% cell death and BV-CMV-p53 at MOI of 200 induced about 
20% cell death (Figure 4.10). However, BV-CMV-p53 (MOI 50) and 10 mM 
NaB combination treatment induced more than 60% cell death after three days. 
The combination therapy showed an advantage of lowering doses of individual 
therapy to achieve the same cytotoxic effect.  
 
4.3.3 Apoptosis in U251 cells treated with baculovirus-mediated p53 and 
/or sodium butyrate 
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In order to investigate the mode of cell death induced by BV-CMV-p53 or NaB 
treatment, we performed several independent experiments to detect early 
apoptosis in these treated cells: TUNEL staining, Annexin-V staining and DNA 
content analysis. Cells were treated with blank medium, NaB (5 mM), 
BV-CMV-p53 (MOI 100), BV-CMV-Luci (MOI 100), NaB combined with 
BV-CMV-p53, or NaB combined with BV-CMV-Luci, respectively, for 24 hr.  
 
Figure 4.11A shows the TUNEL positive cells which indicate early apoptotic 
cells under fluorescence microscope. Figure 4.11B demonstrates the 
quantification analysis of the apoptotic cells. Cells treated with BV-CMV-p53 
(MOI 100) alone or 5 mM NaB alone only gave about 19.1% or 12.5% of 
TUNEL positive cells respectively, while cells treated with combination of 
BV-CMV-p53 (MOI 100) and 5 mM NaB gave about 45% of TUNEL positive 
cells (Figure 4.11B). Thus the combined treatment enhanced twice as much 
early apoptotic cells compared to BV-CMV-p53 treatment alone, or three times 
compared to NaB treatment alone. Similarly, annexin-V staining of cells 
treated with combination of BV-CMV-p53 (MOI 100) and 5 mM NaB showed 
about 22% of early apoptotic cells which was twice the cells treated 
BV-CMV-p53 alone (10%) or four times the cells treated with NaB alone (5%) 
(Figure 4.12A &B). DNA content of treated U251 cells was also analyzed by 
flow cytometry to detect cells with hypoploid DNA (subG0/1) which is indicative 
of apoptotic cells. Figure 4.13 shows that the percentage of subG0/1 cells was 
much increased in cells treated with combination of BV-CMV-p53 and NaB 
(47%) compared to cells with single treatment of BV-CMV-p53 (20%) or NaB 
(17%). This result further confirms the enhanced cell killing effect mediated by 
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combination treatment of BV-CMV-p53 and NaB than individual treatment in 
U251 cells. The different percentage of early apoptotic cells detected in these 
methods with the same dose and time course may be attributed to their 
different sensitivities. These results nevertheless all indicate that the 
combination treatment of BV-CMV-p53 and NaB in p53-deficient tumor cells 
could enhance the apoptotic effect induced by BV-CMV-p53 or NaB alone. 
 
4.3.4 Enhanced anti-tumor effect in vivo by combination of 
baculovirus-mediated p53 and sodium butyrate  
To evaluate the anti-tumor effect by combination of BV-CMV-p53 and NaB in 
vivo, 3 X106 U251 cells in 0.1 ml PBS were injected subcutaneously into both 
left and right flanks of nude mice. After tumor size reached about 5-8 mm in 
diameter, animals were treated with intratumoral injections of 50 µl 1XPBS, 5 
mM NaB alone, 5 X108 BV-CMV-p53 alone, 5 X108 BV-CMV-Luci alone, 5 mM 
NaB combined with 5 X108 BV-CMV-p53, or 5 mM NaB combined with 5 X108  
BV-CMV-Luci, from day 10 post tumor implantation for six consecutive days. 
Tumor size was monitored every other day from day 10 onwards and the tumor 
size at day 10 was taken as the starting reference size. Tumor growth speed 
was calculated by the ratio of the tumor size at indicated day to its starting size 
at day 10. 
 
Figure 4.14A shows that tumor growth was slowed down dramatically when 
tumors were treated with a combination of BV-CMV-p53 and NaB compared to 
other control groups. As shown in Figure 4.14B, at day 28 post tumor 
implantations, tumor growth in the BV-CMV-p53 and NaB combination treated 
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group was about 16 folds over the reference tumor size, whereas it was 25 
folds in BV-CMV-Luci and NaB combination treated group, 23 folds in 
BV-CMV-p53 treated group, 28 folds in NaB treated group and 32 folds in PBS 
treated group. At day 30, before the mice were sacrificed due to the large 
tumor grown in control groups, the tumor growth was about 20 folds in 
BV-CMV-p53 and NaB combination treated group, while about 31-38 folds in 
other groups (Figure 4.14C). BV-CMV-p53 alone or 5mM NaB alone did not 
show much difference on tumor growth retardation when compared to other 
groups. These results showed that combination treatment of BV-CMV-p53 and 
NaB could have enhanced anti-tumor effect in vivo compared to the individual 
















Chapter 4. A Histone Deacetylase Inhibitor Improves Baculovirus-mediated Gene  
Therapy in Glioma 
 
Figure 4.2 Improved baculovirus-mediated luciferase expression by the 
addition of sodium butyrate (NaB) in glioma cells. U251 cells were infected 
with BV-CMV-Luc at MOI of 50 and incubated with the indicated amount of 
NaB. Luciferase assay was carried out one, two or three days later. The results 
are expressed in RLU per milligram of total cell protein and values are 
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Figure 4.3 Increased EGFP-positive cells by the addition of NaB in glioma cells 
infected with BV-CMV-EGFP. U251 cells were infected with BV-CMV-EGFP at 
MOI of 50 and incubated with indicated amount of NaB for one day. Flow 
cytometry was done to detect EGFP expression in cells. The results are 
reported as the percentage of EGFP-positive cells and values are presented 
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Figure 4.4 Increased baculovirus-mediated EGFP expression in U251 cells 
under fluorescence microscopy. Cells were infected with BV-CMV-EGFP at 
MOI of 25 and incubated with indicated amount of NaB for one day. EGFP 
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Figure 4.5 Western blot of baculovirus-mediated p53 expression in U251 cells. 
Cells were treated with BV-CMV-p53 or BV-CMV-Luci at MOI from 0 to 200. 
Western blot was done to detect p53 protein level by using anti-p53 primary 
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Figure 4.6 Western blot of increased baculovirus-mediated p53 expression by 
NaB in U251 cells. Cells were treated with BV-CMV-p53 or BV-CMV-Luci at 
MOI of 100 or blank medium (no virus infection) with the addition of NaB 
indicated in the figure. 24 hr later, western blot was done to detect p53, 
acetylated histone H4 protein by using anti-p53 or anti-acetylated histone H4 
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Figure 4.7 Immunohistochemistry of p53 expression in U251 cells. Cells were 
infected with BV-CMV-p53 or BV-CMV-Luci at MOI of 100 with or without 5 
mM NaB for 24 hr. Cells were also counterstained with Hoechst. BV-CMV-Luci 
was used as a control vector. Mouse anti-p53 and cy3-conjugated anti-mouse 
polyclonal antibody were used as the primary and secondary antibodies 
respectively. Immunofluoresence was directly detected under microscopy 
(Olympus, Japan) and photographs were taken with digital camera attached to 
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Figure 4.8 Dose and time course analysis of glioma cell death induced by NaB 
treatment. U251 cells were treated with NaB at indicated concentration. MTT 
assay was measured 1 day, 2 days or 3 days later. Each point represents the 
average obtained from three independent experiments, with error bars 
representing the SD. 
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Figure 4.9 Dose and time course analysis of glioma cell death induced by 
baculovirus vector carrying wtp53 gene. U251 cells were infected with 
BV-CMV-p53 or BV-CMV-Luci with increased MOI from 10 to 200 and MTT 
assay was measured one, two or three days later. Each point represents the 
average obtained from three independent experiments, with error bars 
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Figure 4.10 Dose and time course analysis of glioma cell death induced by 
combination of BV-CMV-p53 and NaB. U251 cells were treated with 
BV-CMV-p53 (MOI 50) and NaB (0 mM to 20 mM). BV-CMV-Luci was used as a 
virus control. MTT assay was measured one, two or three days later. Each point 
represents the average obtained from three independent experiments, with error 
bars representing the SD. 
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Figure 4.11 TUNEL staining of U251 cells treated with baculovirus and /or NaB. 
A. TUNEL staining of U251 cells infected with BV-CMV-p53 at MOI of 100 with 
or without NaB (5 mM) for 24 hr. BV-CMV-Luci was used as a virus control. 
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Figure 4.11 (continued) B. Quantification of TUNEL staining. Results are 
reported as the percentage of apoptotic U251 cells and values are presented as 
mean with SD. *** p< 0.001 compared to control group treated with NaB alone, 
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a. Blank medium                  d. NaB 
b. BV-CMV-Luci                   e. BV-CMV-Luci+NaB  
 
c. BV-CMV-p53                   f. BV-CMV-p53+NaB 
 
 
Figure 4.12 Annexin-V FITC flow cytometry of U251 cells treated with 
baculovirus and /or NaB. A. Flow cytometry diagrams of U251 cells infected 
with BV-CMV-p53 at MOI of 100 with or without NaB (5 mM) for 24 hr. 
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Figure 4.12 (Continued) B. Quantification of flow cytometry results. Results are 
reported as the percentage of early apoptotic U251 cells and values are 
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a. Blank medium                  d. NaB 
b. BV-CMV-Luci                   e. BV-CMV-Luci+NaB  
 
c. BV-CMV-p53                   f. BV-CMV-p53+NaB 
 
 
Figure 4.13 Flow cytometry of DNA content in U251 cells treated with 
baculovirus and /or NaB. A. U251 cells infected with BV-CMV-p53 at MOI of 100 
with or without NaB (5 mM) for 24 hr, and DNA content was measured by 
propidium iodide staining and subsequent FACS analysis. Cells undergoing 
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Figure 4.13 (continued) B. Quantification of cells in subG0/1. Results are 
reported as the percentage of early apoptotic U251 cells and values are 
presented as mean with SD. X p< 0.5 compared to control group treated with 
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Figure 4.14 Synergistic anti-tumor effects of baculovirus-mediated p53 and 
sodium butyrate in vivo. 3 X106 U251 cells were injected into the back region of 
nude mice subcutaneously. From day 10 after tumor implantation, 50 μl of PBS 
containing baculovirus (5 X108 pfu) and /or NaB (5 mM) was injected into tumor 
mass for six consecutive days. Tumor size was measured by calipers every two 
days before injection, and calculated as (width2) X (length) /2. Tumor growth 
was demonstrated by folds compared to its reference size at day 10 and every 
group consisted of 3-5 nude mice. A. Tumor growth during the treatments. Each 
point represents the average obtained from each group, with error bars 
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Figure 4.14 (continued) B. Tumor growth at day 28 after tumor implantation. C. 
Tumor growth at day 30 after tumor implantation. xx p< 0.1 compared to control 
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4.4 Discussion  
Tumor suppressor gene p53 has been intensively studied because about 50% 
of tumors are found to be p53 defective, for this reason restoration of wtp53 
has become important in cancer gene therapy. HDAC inhibitors, on the other 
hand, are known to be able to induce histone hyperacetylation, reactivate 
suppressed genes, induce apoptosis and thus inhibit aggressive tumor growth, 
although the detailed mechanisms are still under investigation. In current study, 
we showed that baculovirus-mediated p53 gene therapy combined with an 
HDAC inhibitor, sodium butyrate, exhibited enhanced anti-tumor effects on 
human malignant glioma cells containing mutant type p53 gene.  
 
Baculovirus-mediated gene delivery affected by NaB 
The findings that HDAC inhibitors can enhance protein expression from 
baculovirus vectors encouraged people to use them together with baculovirus 
to increase transgene expression level (Condreay et al., 1999). This was 
confirmed by our results showing that baculovirus-mediated luciferase or 
EGFP expression in U251 cells was both greatly enhanced by sodium butyrate 
treatment in a dose dependent manner. Results of flow cytometry and 
fluorescence signal both showed no significnat differences on EGFP 
expression when dose of NaB from 5 mM to 20 mM was used. This could be 
due to the high transduction efficiency (90%) which was almost saturated and 
thus difficult to be further improved. Western blot and immunohistochemistry 
both showed that although p53 expression slightly increased with 
BV-CMV-p53 infection, the addition of sodium butyrate enhanced p53 
expression level markedly. With enough cell lysate loaded, the endogenous 
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mtp53 in U251 was high enough to be detected by immunoblotting; however, 
endogenous p53 was not detected by immunohistochemistry. The difference 
could be explained by the different sensitivity of these two methods.  
 
Increased cytotoxicity by combined treatment with BV-CMV-p53 and NaB 
The cytotoxicity of BV-CMV-p53 treatment alone in U251 cells was not 
significant, achieving about 20-25% cell death at MOI of 200. This was 
consistent with the Western blot result where p53 protein over-expression only 
slight increased with increasing infection MOI, and thus might not induce 
p53-dependent apoptosis significantly. NaB also individually induced mtp53 
glioma cell death in a dose-dependent manner. However, further enhanced 
cell death was observed by combined treatment of BV-CMV-p53 and NaB 
compared to single treatment. Moreover, in order to achieve the same 
cytotoxic effect caused by single treatments, lower dose of BV-CMV-p53 and 
NaB can be used in combination treatment, which is important for safety 
considerations in clinical trials or applications. 
 
The enhanced cell death of combination treatment was supported by 
apoptosis analysis. Although different method had different percentage of 
apoptotic cells which may due to their different sensitivity, TUNEL staining, 
Annexin-V staining and DNA content analysis all showed increased 
percentage of apoptotic cells in cells treated with combination therapy than in 
cells treated with individual therapy as early as 24 hr. In addition, our in vivo 
tumor model study demonstrated an obvious synergistic effect on inhibiting 
tumor growth by the combination therapy of BV-CMV-p53 and NaB, while at 
the same dose single therapy by BV-CMV-p53 or NaB alone did not show 
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significant difference compared to PBS treatment, which may be due to the low 
dose of individual therapy we used in this study.  
 
Possible mechanisms of enhanced anti-tumor effects by BV-CMV-p53 
and NaB 
With regard to the mechanisms for the synergistic anti-tumor effect of 
combination therapy, there are several possibilities. One is that p53 and NaB 
killed tumor cells individually via different apoptosis pathways, which could 
complement each other. HDAC inhibitors have been reported to activate 
intrinsic apoptotic pathway (Bernhard et al., 1999; Ruefli et al., 2001; Vrana et 
al., 1999). Recently, HDAC inhibitors are reported to mediate apoptosis via 
specific death pathways that involves FAS /FAS ligand or the tumour necrosis 
factor-related apoptosis inducing ligand (TRAIL) (Insinga et al., 2005; Kwon et 
al., 2002; Nebbioso et al., 2005). Chopin et al. reported that sodium butyrate 
induced p53-independent, Fas-mediated apoptosis in MCF-7 human breast 
cancer cells (Chopin et al., 2002). Terui et al. showed that sodium butyrate 
induced apoptosis via p53 acetylation (Terui et al., 2003). In these reports, 
function of p53 was shown to be unnecessary in induction of apoptosis by 
HDAC inhibitors, and thus HDAC inhibitors may provoke apoptosis through 
different mechanisms in different cell types. The ability of HDAC inhibitors to 
induce both p53 dependent and independent apoptosis pathways made them 
useful for killing tumor cells irrespective of p53 status. However, the detailed 
mechanisms of apopotosis induction by HDAC inhbitiors are still under 
investigation, and different HDAC inhibitors may induce apoptosis through 
different pathways in various cell types. 
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The second possible reason is that with wtp53 over-expression in mtp53 tumor 
cells, p53 restoration might induce chemosensitivity of the tumor cells to NaB 
chemotherapy. It has been reported that wtp53 restoration sensitized the host 
and tumor cell response to radiation and chemotherapy (Cascallo et al., 2005; 
Dorigo et al., 1998; Gallardo et al., 1996; Nishizaki et al., 2001). Combination 
of p53 therapy and chemotherapy or radiation therapy has been reported to 
have synergistic anti-tumor effect (Cascallo et al., 2005; Dorigo et al., 1998; 
Fujiwara et al., 1994; Gallardo et al., 1996; Inoue et al., 2000; Nishizaki et al., 
2001; Osaki et al., 2000; Song and Boyce, 2001). Thus baculovirus-mediated 
wtp53 therapy may also sensitize tumor cells to sodium butyrate due to its 
restoration, which makes our combination therapy more feasible to achieve 
synergistic effects.  
 
Another possibility of the synergistic effect by our combination therapy is the 
further over-expression of baculovirus-mediated p53 by NaB. The increased 
p53 over-expression could not only further enhance p53-dependent apoptosis, 
but further enhance the chemosensitivity of tumor cells to NaB. This beneficial 
relationship between baculovirus-mediated p53 gene therapy and NaB 
chemotherapy offers a more feasibility to achieve enhanced effects. However, 
further work is necessary to confirm these hypotheses. 
 
P53 gene therapy and chemotherapy 
It has been speculated that p53 gene therapy may not be so effective with 
malignant cells which express wild type p53, and some previous work has 
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confirmed this speculation (Gomez-Manzano et al., 1996; Lang et al., 1999). 
Lang et al. demonstrated adenovirus-mediated p53 gene transfer into gliomas 
with mutant p53 resulted in massive apoptosis. However, wild type p53 glioma 
cells were resistant to the apoptotic effects of p53 transfer (Lang et al., 1999). 
However, Li et al. reported that presence of endogenous wild type p53 does 
not preclude apoptosis by over-expression of exogenous p53 in glioma cells 
and found glioma cells containing wild type p53 also underwent apoptosis after 
adenovirus-mediated p53 gene therapy (Li et al., 1999; Li et al., 1997). In our 
current study, we did not examine tumor cells with wild type p53. However, if 
p53 gene therapy alone also could kill glioma cells containing wtp53, it would 
be only beneficial to p53 gene therapy of wtp53 tumors, because as we know 
many tumors including high-grade glioblastoma multiforme carry a functionally 
intact p53 gene. However, further investigations need to be done to confirm 
whether p53 gene therapy is applicable to functionally intact p53 tumors.  
 
Although it has been suggested an important role of p53 status on 
chemotherapy response in cancer cells, there are still some controversial 
reports about the influence of p53 status on chemo-sensitivity. It was reported 
that cancer cell lines with mutant p53 tended to be less sensitive to 
chemotherapy than those with the wild type p53 (O'Connor et al., 1997). 
However, some studies produced conflicting results by showing that p53 
inactivation in cancer cells led to increased sensitivity to chemotherapeutic 
agents (Gupta et al., 1997; Hawkins et al., 1996). The different outcome of 
studies could be caused by the difference in methodology and different types 
of tumor cells as well as the drugs. Nevertheless, it also may indicate that p53 
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status alone is insufficient to determine sensitivity or resistance to cytotoxic 
drugs (Yu, 2006). 
 
Previous studies that investigated the effect of p53 gene therapy combined 
with chemotherapy mostly used adenovirus to deliver p53 gene, and some 
beneficial efficacy of the combination was reported (Cascallo et al., 2005; 
Fujiwara et al., 1994; Inoue et al., 2000; Okegawa et al., 2005; Osaki et al., 
2000; Takimoto et al., 2005). Within these reports, few of them applied HDAC 
inhibitors as chemotherapy. One study reported that an augmented anti-tumor 
effect was observed in vitro as well as in vivo when sodium butyrate was 
combined with adenovirus mediated p53 expression (Takimoto et al., 2005). 
However, they administrated the sodium butyrate intraperitonially with a quite 
high concentration (500 mM). Although sodium butyrate has been reported to 
be nontoxic in trials for leukemia (Warrell et al., 1998) , and Takimoto et al. 
also claimed that no apparent side effects were observed in treated mice, it is 
always preferred to reduce the dose of chemotherapy as much as possible for 
safety consideration. Another study reported that histone deacetylase inhibitor 
FR901228 increased the efficiency of adenoviral gene therapy in bladder 
cancer in vitro and in vivo. In their study, the concentration of FR901228 
showing no or minimal cytotoxicity was selected, which increased the 
sensitivity of tumor cells to adenovirus-mediated p53 gene therapy (Okegawa 
et al., 2005). However, gene delivery using adenovirus vectors is problematic 
due to safety and toxicity of adenovirus. This is why we considered baculovirus 
to be a much safer option for gene delivery. One recent work reported the use 
of baculovirus vectors carrying the p53 gene with an anti-cancer drug, 
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adriamycin, to kill human osteogenic sarcoma cell line Saos-2 in vitro (Song 
and Boyce, 2001). Saos-2 cells were found to be highly susceptible to infection 
with baculovirus, with nearly 100% of gene delivery efficiency at MOI 30 (Song 
and Boyce, 2001). This is much higher than our U251 cells whose baculovirus 
gene delivery efficiency is about 30-40% at MOI 50. In their study, 
baculovirus-mediated p53 at MOI 160 induced about 60% cell death, and 
when combined with adriamycin (35 ng/ml), BV-p53 at MOI of 100 induced 
greater than 95% cell death (Song and Boyce, 2001). This indicates that 
susceptibility is an important factor to consider the gene delivery vector in 
order to achieve optimal therapeutic effects. However, this problem could be 
overcomed by our combination therapy, because with histone deacetylase 
inhibitors, baculovirus-mediated gene delivery efficiency in U251 cells could be 
greatly enhanced. In addition, the most attractive characteristic of HDAC 
inhibitors compared with other chemotherapy is their tumor selective 
cytotoxicity, which is thought to function through disruption of cell cycle 
checkpoints (Warrener et al., 2003). HDAC inhibitors can trigger a G2-phase 
checkpoint response in normal cells but are cytotoxic in tumor cells in which 
this checkpoint is defective (Warrener et al., 2003). Liu et al. recently reported 
that co-intravenous injection of depsipeptide, a HDAC inhibitor, with 
PEI-mediated p53 complexes selectively targeted tumors at both the tissue 
and cellular levels, without requiring the use of ligand- or promoter-based 
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HDAC inhibitors comprise several structural classes of compounds. Sodium 
butyrate has been extensively studied and was firstly approved for use in the 
clinic. However, the butyrates such as sodium butyrate are not very ideal 
agents because of a short plasma half-life and the relative high concentrations 
required (millimolar) to achieve inhibition of HDAC activity. In addition, as 
different HDAC inhibitors play different roles in different cell types, some kinds 
of HDAC inhibitors may not have sufficient anti-glioma effect at clinically 
applicable doses. Thus developing and choosing appropriate HDAC inhibitors 
for specific cancer such as GBM should be another challenge. More and more 
novel HDAC inhibitors are currently being identified, synthesized and 
characterized for cancer therapy. 
 
Targeted gene delivery is necessary in order to limit side effects to neighbor 
healthy cells, especially in the brain which is complicated by a broad diversity 
of cells. Thus further modifications of baculovirus vector are needed to achieve 
this purpose. One possibility is to use cell type specific promoter, however, till 
now, no specific promoter has been found for glioma cells. Considering most 
malignant gliomas are derived from astrocytes, glial fibrillary acidic protein 
(GFAP) promoter could be a good choice to restrict the therapeutic gene in 
astrocytes, without affecting neurons. Our previous study showed that using a 
hybrid CMV E/GFAP promoter in the context of baculovirus vector, strong and 
specific gene delivery into glioma cells could be achieved (Wang et al., 2006). 
However, normal astrocytes could also be targeted with this promoter, thus 
more specific promoters to glioma cells are still in great demand. With 
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development of advanced technologies such as microarray technology, we 
believe that our dream would come true in the near future. 
 
Novel treatment like gene therapy is a promising method to treat maglinant 
tumors; however, combination therapy is still necessary to achieve optimal 
anti-tumor effects. Our strategy to combine baculovirus-mediated p53 gene 
therapy and HDAC inhibitor therapy together is a novel strategy to treat p53 
deficient maglinant tumors especially gliomas which are fairly resistant to 
conventional therapies such as surgery, radiotherapy and chemotherapy. This 
combination strategy not only enhances apoptotic effects induced by individual 
treatment, but also may sensitize tumor cells to each treatment. Although 
further investigations on the detailed mechanisms between HDAC inhibitors 
and baculovirus vectors are necessary and further modifications of baculovirus 
vector are also needed to target specific tumor cells, our strategy provides 






















































Chapter 5. Conclusion 
As chemical compounds are becoming hot for the development of gene 
delivery vectors, this study was undertaken to explore the possibility of using 
common chemical drugs or molecules to assist gene delivery vectors for 
improved efficiency in CNS. We mainly focused on the PEI-mediated non-viral 
vector and the baculovirus-mediated viral vector. 
 
As the cytotoxicity problem has limited the application of efficient PEI-mediated 
gene delivery which is often achieved by high MW PEI, it is important to 
develop novel PEI polymers with increased transfection efficiency as well as 
reduced cytotoxicity. In chapter two, we examined the possibility of using a 
novel copolymer PEI600-CyD, in which the low MW PEIs were linked by β- 
CyD, as a non viral vector in CNS. PEI600-CyD demonstrated improved 
efficient transgene expression which was much higher than unmodified 
PEI600 and was also almost comparable to PEI 25kDa in vitro and in vivo. In 
addition, it maintained the low toxicity character of PEI 600 compared with that 
of PEI 25kDa. This part of work demonstrates a good strategy to solve the 
incompatible efficiency and cytotoxicity problem of PEI and it opens a new 
window to produce novel non-viral vectors with novel functions or characters 
through chemical modifications.  
 
MDR, caused by over-expression of PGP, has been an obstacle for drug 
delivery into tumor cells. In chapter three, to explore the possibility of applying 
and improving non-viral vector gene therapy for drug resistant tumors, we 
examined the effect of PGP on PEI-mediated non-viral vector in vitro and 
developed a new approach to improve PEI-mediated gene delivery efficiency 
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by inhibiting PGP function with chemical or biological molecules. We 
demonstrated that the PGP-positive tumor cells had much lower PEI-mediated 
transgene expression compared with PGP-negative tumor cells, and inhibition 
of PGP function or expression in PGP-positive cells using a chemical PGP 
inhibitor verapamil or siRNA targeting MDR1 greatly increased transgene 
expression. These results indicate that PEI/DNA complexes may be PGP 
substrates and inhibition of PGP by chemical drugs or biological molecules can 
enhance PEI-mediated gene delivery efficiency. Our work also implies that 
PGP not only acts as a barrier for chemotherapy in PGP-positive tumor cells, 
but as an obstacle for PEI-mediated gene therapy. It would be necessary to 
inhibit PGP function or expression in order to improve cationic polymer-based 
gene delivery efficiency. 
 
With the ability to affect epigenetic gene regulation, histone deacetylase 
inhibitors such as sodium butyrate have often been applied in 
baculovirus-mediated gene delivery system to enhance gene delivery 
efficiency. The final part of this thesis investigated the feasibility of combining 
baculovirus gene therapy with sodium butyrate chemotherapy to achieve 
enhanced therapeutic effects in gliomas both in vitro and in vivo. Results 
showed that sodium butyrate not only had anti-tumor effect itself in glioma cells, 
but also enhanced baculovirus-mediated reporter gene expression as well as 
therapeutic gene wtp53 expression in these cells. The treatment of combining 
baculovirus-mediated wtp53 gene therapy with sodium butyrate showed much 
enhanced anti-tumor effect when compared with baculovirus treatment or 
sodium butyrate treatment alone in p53 deficient glioma cells. Moreover, the 
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combination therapy reduced the dosage of individual treatment which made it 
much safer for patients. This study demonstrates a promising approach for 
brain cancer gene therapy by combining baculovirus with HDAC inhibitors. 
Further exploration and optimization in animal studies and preclinical trials 
should be necessary for future applications.  
 
In conclusion, our study explored and confirmed the possibility of improving 
PEI- and baculovirus-mediated gene delivery efficiencies through chemical 
modifications or combinations in CNS. The approaches in our study should 
contribute to a better understanding of assisting gene delivery vectors for 
improved efficiencies, and have provided useful information for future gene 
therapy applications. Through opening a new wave of modifications for gene 
delivery systems, chemical compounds or drugs are representing exciting 
prospects for a more rational approach to gene therapy. 
 
Future work 
As discussed in every section, more investigations are needed to be done for 
further improved gene delivery vectors, especially for particular gene therapy 
applications. 
 
1. For our novel copolymer PEI600-CyD, we only focused on the gene 
delivery efficiency. Thus further explorations and modifications such as 
chemically conjugating polymer with targeting ligands would be necessary 
if cell type specific gene delivery is desired. In vivo applications by 
choosing appropriate gene delivery route should also be optimized. 
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2. To overcome MDR in PEI-mediated gene therapy for brain tumors, 
appropriate PGP inhibitors with low toxicity as well as improved specificity 
should be applied. Thus PGP inhibitors with better properties should be 
developed, and further preclinical and clinical trials should be done to 
demonstrate their safety and efficacy.  
 
3. In addition to PGP, other ABC transporters such as MRP1 are also 
abundantly expressed in CNS and in most gliomas. For future brain tumor 
gene therapy especially glioma gene therapy, detailed relationship 
between these molecules and PEI-mediated gene delivery complexes 
should be elucidated. 
 
4. There are conflicting reports available on the sensitivities of mtp53 tumor 
cells and wtp53 tumor cells to p53 gene therapy. In current study, we only 
applied baculovirus-mediated p53 gene therapy and HDAC inhibitors 
chemotherapy in mutant type gliomas. Gliomas containing wild type p53 
gene may also be worth investigation by this method as we know the other 
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